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ABSTRACT 
 
 
 Pediatric formulations have received great attention from regulatory agencies in 
the United States and Europe. Since solid dosage forms such as tablets and capsules will 
not be able to improve pediatric patients’ compliance, customized pediatric formulations 
are needed. In response, formulators in the pharmaceutical industry have made significant 
effort into developing various pediatric formulations. However, developing satisfactory 
pediatric formulations is a process that is guided by case by case basis.  
 
 The objective of this current study was to apply the scientific pharmaceutical 
technology concepts into developing modern pediatric formulations. We have shown that 
the drug delivery design will be affected by the route of administration and by the type of 
dosage form utilized. We are hopeful that our approach will serve as a tool to assist 
formulations development. Three drug molecules and an anion were utilized in this work 
(Chlorpheniramine Maleate, Prednisone, Sulfamerazine, and Iodide ion). Each drug 
molecule was utilized according to its physicochemical properties along with the 
pediatric patients’ needs. As a result, several pediatric formulations were developed. Here 
is the list: taste masked orally disintegrating tablet, taste masked orally disintegrating film, 
taste masked mini-tablet, reconstituted nanocrystals and a transdermal microemulsion. 
We are hopeful that these dosage forms will serve as good examples for specialized 
pediatric formulations and will attract pharmaceutical industry to adapt some these 
delivery systems into their development strategy. 
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CHAPTER 1.    INTRODUCTION 
 
 
Due to the lack of pediatric formulations, the regulatory agencies have initiated 
continual emphasis on the necessity for developing novel pediatric formulations. In 
response, pharmaceutical companies have developed various novel pediatric formulations 
some of which have already been launched into the market. 
 
 To develop a satisfactory pediatric formulation, an appropriate route of drug 
administration is the prerequisite and can be selected from one of the followings: oral, 
topical/transdermal, buccal, rectal, nasal, pulmonary, ocular, injectable, etc.1 
 
 
1.1. Oral Pediatric Formulation 
 
 In general, oral delivery of pediatric drugs is preferred over other delivery routes 
since it is convenient, economical, and user-friendly. Based on Strickley and co-workers’ 
classification,1 pediatric oral formulations were divided into two types: (1) Ready-to-Use 
formulations, which do not need manipulation prior to dosing; (2) Manipulation-Required 
formulations, which require manipulation under some instructions prior to dosing. In 
contrast to regular adult oral formulations such as tablets and capsules, pediatric oral 
formulations are likely to contain some specific features to achieve good patient 
compliance for pediatrics. In response, several customized oral pediatric formulations 
were by far developed. 
 
 
1.1.1. Orally disintegrating tablets (ODTs) 
 
ODTs are designed to disintegrate in the oral cavity instead of the GI tract and 
therefore a rapid disintegration, usually in less than a minute, is necessitated under the 
exposure of saliva. Previous studies indicated that there has been a remarkable growth of 
ODT demand since the majority of patients preferred (more than 85% of patients) and 
would purchase ODTs (70% of patients) rather than other regular tablet formulations.2 
ODTs can be produced by different techniques, which include freeze-drying process, 
molding/cotton-candy process, and compaction process.3 To scale-up ODT preparation, 
conventional tablet compression method and instrument with some modifications are 
applicable.4 
 
 Unlike regular tablets needed to be swallowed integrally, ODTs eliminate the 
necessity of tablet swallowing and thus fairly suitable for elder children. It is worth 
noting that several ODT products have already been launched to commercial market for 
pediatrics such as Prevacid® (lansoprasole), Zofran® (ondansetron), and Clarinex® 
RediTabs® (desloratadine).1 In view of challenges of ODT development, one obstacle 
attributes to the unpleasant taste of some APIs that is essentially associated to taste 
masking. Tablet film-coating is not applicable for ODTs since ODT is disintegrated in the 
oral cavity and consequently unpleasant taste of drug is sensed. Coating in the powder 
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level is one approach to achieve taste masking for ODTs. Xu and co-workers developed 
Famotidine: Eudragit® EPO: colloidal silicon dioxide: polyethylene glycol 400 
microspheres using spray-drying technique and then these microspheres are incorporated 
into ODTs.5,6 Conversely, Khan and co-workers prepared ondansetron HCl in  
Eudragit® EPO complex using precipitation method, followed by formulating ODTs. 
Moreover, if drug content is relatively low in ODTs (less than 20 mg), the addition of 
flavors and sweeteners is another feasible approach.1 
 
 
1.1.2. Film strips/Orally disintegrating films (ODFs) 
 
 The first ODF product (Listerine PockerPaks®) was introduced to the market by 
Pfizer in 2001 and over time this novel formulation has gained more interest on 
popularity. ODF is a film strip which disintegrates rapidly on the tongue without being 
chewed or being swallowed. Therefore, ODFs can be administered by pediatric patients 
at ease. Two techniques have been developed to prepare ODFs, including casting method 
and hot-melt extrusion method. Casting method involves dissolution and/or dispersion of 
active pharmaceutical ingredients (APIs) and various excipients in an aqueous medium, 
medium casting, and drying. Hot-melt extrusion method, as the relatively new method, 
includes extrusion of melted drug and/or polymers’ complex, casting, cooling, and drying. 
In order to develop a satisfactory ODF, various excipients are desirable to obtain 
acceptable performance such as robustness, content uniformity, taste masking, rapid 
disintegration, appearance, etc.7 Film-forming polymer is the primary component of ODF 
and play a critical role in film’s mechanical properties. A number of polymers were 
utilized individually or in a combination as the backbone of film strips and these 
polymers include modified starch (maltrodextrin),8,9 hypromellose,10 andpyrrolidone.11 In 
addition, a balance of plasticizer and surfactant in film’s formula is pursued to exhibit 
good spreadability and elasticity properties. Taste masking should be reached if APIs in 
the ODF are unpleasant. The addition of taste masking agents is the most prevalent way 
to attenuate the undesirable taste. On the other hand, the method of coating in the powder 
level may be employed for the purpose of taste masking since microparticles could be 
incorporated in film matrix successfully.12 
 
 
1.1.3. Mini-tablets 
 
Apart from ODT and ODF, mini-tablet is another option to achieve formulation 
swallowability for pediatric patients. Mini-tablet is defined as a tablet with a diameter 
less than 3 mm.13 As a replacement of regular tablets, mini-tablets can be swallowed by 
children less than 10 years old at their ease.14 
 
 There is a potential for mini-tablets to be applied widely as a pediatric 
formulation due to (1) its unique advantages such as regular shape, good appearance, 
acceptable mechanical properties, and uniform content; (2) the feasibility of mini-tablets 
(1 mm and 2 mm in diameter) manufacturing using regular tablet compression machine.15 
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In addition, mini-tablets were utilized in other drug route of administration instead 
of oral. For example, some researchers applied coated mini-tablet as an ophthalmic insert 
for drug control release in eyes.16 
 
 
1.1.4. Nanocrystals (constituted to a suspension) 
 
 Powder (granule) is a type of “Manipulation-required formulation” and has been 
utilized very commonly as a pediatric formulation. Prior to the application, this 
formulation is necessary to be constituted to a suspension formulation. Apart from API 
powder, other excipients can also be added into the powder blend, including flavor agents, 
color agents, sweeterners, dispersing agents, buffering agents, preservatives, viscosity 
modifiers, etc.1 
 
In contrast to regular powder in micron level, nanoparticle has an increase of 
dissolution rate and saturated solubility, especially for poorly soluble APIs, which may 
result in higher oral bioavailability. Moreover, nanoparticles are easier to adhere to GI 
membrane and consequently enhance oral bioavailability further.17  
 
 Currently there are several techniques for yielding nanosuspensions. In general, 
these methods can be divided into two main categories: “bottom-up” technology and 
“top-down” technology. The “bottom-up” technology basically is those methods via 
recrystallizing nanocrystals from solution. Due to inherited limitations of “bottom-up” 
technology such as wide variation in particle size distribution, solid state transformation 
(unstability), and scale-up difficulty, this technology is not widely applied.18 On the other 
hand, the “top-down” technology such as wet bead milling and high pressure 
homogenization which involves methods about reducing particle size from micron range 
is more popular. Wet bead milling involves the milling process of powders in aqueous 
medium by colliding with glass/pearl beads. Conversely, high pressure homogenization is 
a relatively new technology and nanoparticles are achieved using more sophisticated 
equipments. One example is the microfluidizer, where particles were milled by two high-
velocity jet streams. The other most-common equipment is piston-gap homogenisers. In 
this equipment, a drug solution is pushed through a gap by the aid of large force applied 
by a piston, followed by the boiling of liquid droplets. Sequentially these gas bubbles 
fracture with the formation of nanocrystals.19 
 
 
1.2. Transdermal Formulations 
 
When oral or parental route of administration is inapplicable or encountered with 
insufficient patient compliance, alternative routes such as transdermal delivery is pursued 
with good pediatric patient compliance. 
 
Transdermal delivery has been utilized for several decades and considered as a 
non-invasive route of administration. Although, transdermal delivery is utilized in several 
clinical situations, the main challenge for this delivery route has always been the drug 
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dose and the skin permeability since skin function as a barrier to prevent external 
invasions. Nanotechnology has been utilized in transdermal drug delivery to improve 
permeation; and microemulsion is considered the second most popular colloidal system 
which has been used for dermal applications.20 
 
 Microemulsion is a multicomponent system composed of water, oil, surfactant, 
and cosurfactant.21 Here, we mention several advantages of microemulsions: First, the 
procedures for preparing microemulsions are simple, inexpensive, and rapid. Second, 
microemulsions have shown to enhance the permeability of hydrophobic and hydrophilic 
compounds,22 either by decreasing the skin resistance or by increasing the concentration 
gradient of the drug diffusion.23 In addition, the nano-size droplets of microemulsion are 
more likely to adhere to the skin surface and penetrate into the skin.22 In addition, 
microemulsions as compared to regular emulsions (microns size), are thermodynamically 
stable during storage, packaging, and transportation due to the lack of fixed curvature and 
the low interfacial tension. 
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CHAPTER 2.    EVALUATION OF CHLORPHENIRAMINE MALEATE 
MICROPARTICLES IN ORALLY DISINTEGRATING FILM AND ORALLY 
DISINTEGRATING TABLET FOR PEDIATRICS﹡ 
 
 
2.1. Introduction 
 
 In recent years, pediatric formulations have gained more attention from private 
and governmental institutes. Although there were many governmental incentives offered 
to pharmaceutical companies to design and improve new pediatric formulations, 
developing a satisfactory pediatric formulation is still a challenging task for many reasons: 
(1) Overwhelming majority of active pharmaceutical compounds are poorly soluble 
and/or poorly absorbable which cause low bioavailability; (2) Some pediatric 
formulations such as powders or granules have tremendous dose strength fluctuations 
while dosing; (3) Swallowing appropriateness may not be achieved easily for children 
less than 10 years of age; (4) Many active pharmaceutical compounds or excipients have 
unpleasant taste.1 Despite critical issues such as low solubility/stability and dose strength 
fluctuations, swallowing inappropriateness and unpleasant taste are the two most critical 
obstacles that cause very low patient compliance, specifically for the pediatric patients.  
 
 Since a large number of active pharmaceutical ingredients have unpleasant taste, 
various methods have been developed by formulation scientists to attenuate the 
undesirable taste. It has been reported that appropriate flavors, sweeteners, and amino 
acids were simply incorporated into the formulations for the purpose of taste masking.24 
Lipophilic vehicles were typically used to prevent the contact between bitter taste drug 
molecules with taste buds on the tongue by way of inhibiting the sense of bitterness.24 
Complexing agents such as cyclodextrin were used to bind bitter taste drug molecules 
inside its hydrophobic cavity to mask bitterness.25,26,27 Taste masking was also achieved 
via binding of drug molecules into ion-exchange resins.24,28 Apart from all these above 
mentioned taste-masking techniques, the utilization of a pH-dependent polymer as a 
coating material to avoid the contact between taste buds on the tongue with bitter tasting 
drugs is a feasible and economic approach. Selectively, Eudragit® EPO, a pH-dependent 
copolymer, is insoluble in saliva (pH 6.8) but dissolves rapidly in gastric fluid (pH 1.5-2). 
Therefore, film coating with Eudragit® EPO can inhibit the release of drug from a tablet 
in the saliva and mask the bitter taste.29 This polymer was also used as a moisture 
protectant during tablet coating.29 Additionally, Eudragit® EPO is suitable for powder 
coating. In contrast to other techniques of making microparticles, spray drying technique 
has a continuous, automated and quick process for producing products and therefore can 
be scaled up for industrial uses. In the past, API-Eudragit® EPO has been utilized to 
synthesize microparticles for masking the unpleasant taste of drug powders and loaded 
 
 
﹡: Adapted with permission. Lou H, Liu M, Qu W, Hu Z, Brunson E, Johnson J, 
Almoazen H. Evaluation of chlorpheniramine maleate microparticles in orally 
disintegrating film and orally disintegrating tablet for pediatrics. Drug Dev Ind Pharm. In 
Press. 
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into oral dosage forms.5,6 In this study, we selected orally disintegrating tablet (ODT) 
because ODT are different from traditional tablets since they are designed to disintegrate 
in the oral cavity instead of the GI tract. Therefore, pediatric patients can avoid 
swallowing a whole tablet and consequently enhance patient compliance. However, some 
pre-school children still have difficulty grasping skills of administering ODT because 
they cannot follow instructions such as “no swallowing” or “no chewing” properly. This 
makes orally disintegrating film (ODF) a viable option. ODF is a film strip which 
disintegrates rapidly on the tongue without being chewed or being swallowed. In contrast 
to ODT, ODF can be administered to pediatric patients with more ease since it is likely 
that users are already familiar with the use of this category of products by using breath-
freshening strips.7 It is noted that the manufacturing process of ODT is much simpler and 
more cost-efficient as compared to that of ODF. To prepare ODF, either solvent casting 
method with solvent involvement or hot-melt extrusion method with external heat input is 
needed.7 In contrast, ODT can be directly compressed from powder blends without 
solvent or heat. Here we claim that both of these formulations are suitable for pediatric 
populations with some inherited advantages and disadvantages. 
 
In this study, Chlorpheniramine Maleate was chosen as the model drug since it 
has been widely used as an antihistamine drug for pediatric patients. This drug is highly 
water soluble and has acceptable bioavailability.30 However, it is still difficult to develop 
satisfactory pediatric formulations such as ODT and ODF without masking the bitter taste 
of Chlorpheniramine Maleate. 
 
The objective of this study was to develop satisfactory ODT and ODF 
formulations that could mask the taste of Chlorpheniramine Maleate. For this purpose, 
API-Eudragit® EPO microparticles were synthesized using the spray drying technique. 
The formulation of microparticles was optimized depending on two criteria (relatively 
high encapsulation efficiency and low drug release rate). Furthermore, although the 
feasibility of compressing microparticles with other excipients into ODT has been 
reported by others,5,6 incorporating microparticles into ODF has not been investigated. In 
this study, we evaluated the feasibility of microparticle incorporation into both ODT and 
ODF formulations. 
 
 
2.2. Experimental Procedures 
 
 
2.2.1. Materials 
 
Polyvinyl alcohol and Tween 20 were purchased from Sigma Aldrich (MO, USA). 
Chlorpheniramine Maleate was purchased from Spectrum chemical (NJ, USA). Glycerin 
was purchased from Fisher Scientific (MA, USA). Eudragit® EPO was kindly donated 
by Evonik (NJ, USA). Spray-dried Mannitol was kindly donated by SPI Polyols Pharma 
(DE, USA). Lycoat® RS720 was kindly donated by Roquette (IL, USA). Croscarmellose 
sodium was kindly donated by FMC Biopolymer (PA, USA). Magnesium Stearate was 
kindly donated by Mallinckrodt (MO, USA). 
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2.2.2. Preparation of microparticles 
 
API-Eudragit® EPO microparticles were prepared using the spray drying 
procedure conducted by Mohanan et al. with minor modification.31 Briefly, 250 mg of 
Chlorpheniramine Maleate were weighed and dissolved in 5 mL of distilled water 
(aqueous phase). Preset amount of Eudragit® EPO was weighed and dissolved in preset 
volume of dichloromethane (organic phase). The above two phases were mixed by 
manual shaking and emulsified under ultrasonication for 1 minute (QSonica LLC, CT, 
USA). Sequentially the obtained w/o emulsion was immediately spray dried with a mini 
spray dryer B-290 (Buchi, Switzerland). Spray drying parameters were set accordingly: 
aspirator 100%, pump speed 25%, inlet temperature 50 °C, and pre-set compressed gas 
flow (indicated by the rotameter Q-flow). Q-flow was applied to disperse solution into 
fine liquid droplets at the tip of two-fluid nozzle. Values of the weight ratio of Eudragit® 
EPO to drug, the volume ratio of dichloromethane to water, and gas flow (Q-flow) were 
selected as depicted in Table 2-1. At the end of spray drying, microparticles were 
collected, rinsed with 1% PVA solution, and then dried at room temperature under 
vacuum for 24 hours. All harvested dry microparticles were kept at 4 °C in isolated vials 
for further use. 
 
 
2.2.3. Design of experiments 
 
Physicochemical properties of microparticles are influenced by formula 
composition and by process variables. To optimize the microparticle formulations 
properties, an orthogonal experimental mathematical design L9 (33) was conducted as 
shown in Table 2-1.  
 
The weight ratio of Eudragit® EPO to Chlorpheniramine Maleate was defined by 
the independent variable (X1), the volume ratio of dichloromethane to water was defined 
by the independent variable (X2), and Q-flow (in millimeter) was defined as the 
independent variable (X3). Three levels were selected for each independent variable. 
Each experiment for the same level was duplicated. Drug encapsulation efficiency and 
percentage of drug released at 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, and 24 h were selected as the 
key responses. Polynomial equations including linear model Equation 2-1 and quadratic 
model Equation 2-2 were utilized to fit the observed results using SAS software (SAS 
institute INC, NC, USA). The best-fit model was selected based on the multiple 
correlation coefficient (R2), coefficient of variation (CV), adjusted multiple correlation 
coefficient (adjusted R2), and multi co-linearity of predictor variables. Bias was checked 
by comparing predicted and observed responses.  
 
Y=k+aX1+bX2+cX3     (Eq. 2-1) 
 
Y=k+aX1+bX2+cX3+dX1X2+eX1X3+fX2X3+gX12+hX22+iX32 (Eq. 2-2) 
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Table 2-1. Experiment formulations and the levels of variables according to an 
orthogonal experimental design L9 (33). 
 
Formulation 
Variables/Levels 
X1 X2 X3 
1 5 3 30 
2 5 5 37.5 
3 5 7 45 
4 7.5 3 37.5 
5 7.5 5 45 
6 7.5 7 30 
7 10 3 45 
8 10 5 30 
9 10 7 37.5 
 
X1: The weight ratio of Eudragit® EPO to drug while keeping drug amount constant; 
X2: The volume ratio of dichloromethane to water while keeping the volume of water 
constant; 
X3: Q-flow (mm). 
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2.2.4. Drug encapsulation efficiency 
 
Dry microparticles (12.5 mg) were accurately weighed and dissolved in 25 mL of 
80% acetonitrile with aid of sonication. The solution was filtered through a 0.22 µm 
micro-porous membrane filter. Drug concentration was determined at 262 nm using a UV 
spectrometer (PerkinElmer, MA, USA). This experiment was repeated in three replicates. 
The drug encapsulation efficiency (%) was calculated according to Equation 2-3. 
 
Drug encapsulation efficiency (%)= Actual  drug  loadingTheoretical  drug  loading ×100      (Eq. 2-3) 
 
 
2.2.5. In vitro release testes 
 
Dry microparticles (150 mg) were weighed and transferred into a dissolution 
basket wrapped with a 0.45 µm micro-porous membrane filter. The modified basket 
loaded with sample was suspended in 50 mL of simulated saliva (pH=6.8) under constant 
mild mechanical shaking at 37 °C. One milliliter was withdrawn at predetermined time 
points (1 h, 2 h, 3 h, 4 h, 8 h, 12 h, and 24 h), and an equal volume of fresh simulated 
saliva was replaced after each sampling point. Each retrieved sample was filtered through 
a 0.22 µm micro-porous membrane filter, and then was analyzed by UV 
spectrophotometer at 262 nm after appropriate dilution.  
 
 
2.2.6. Checkpoint analysis 
 
 Three variable checkpoints at three (X1, X2, X3) levels: (7.5, 5, 37.5),  
(8.75, 6, 41.25) and (10, 3, 37.5) were selected to validate and verify the robustness of the 
simulation model. Three replicates were performed for each checkpoint. Predicted and 
observed drug encapsulation efficiency values were compared using the Student t test. In 
addition, by comparing the predicted and observed drug release profiles, the dissolution 
profile similarity factor (f2) was calculated according to Equation 2-4 and the application 
condition of f2 was specified to this experiment. Predicted and observed release profiles 
were considered similar if f2 value was ≥50. 
 
f2=50×log{[1+(1/n)∑ (Rt − Tt)𝑛𝑛𝑡𝑡=1 2]-0.5×100}  (Eq. 2-4) 
 
Where n is the number of time points, Rt is the predicted percentage of drug release at tth 
time point, Tt is the mean observed percentage of drug release at tth time point. 
 
 
2.2.7. Preparation of ODF and ODT 
 
ODF were casted based on the compositions presented in Table 2-2. Briefly, 
Lycoat RS720® was dissolved in a solution containing pre-calculated amounts of water, 
glycerin and Tween 80 under manual stirring. Microparticles (or Chloropheniramine 
Maleate powders) were uniformly dispersed (or dissolved) into the solution. This sample  
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Table 2-2. Composition expressed as (w/w %) for orally disintegrating film and orally disintegrating tablet formulations. 
 
Formulation Film  
(Control) 
Film 
(Microparticle) 
ODT  
(Control) 
ODT 
(Microparticle) 
Drug only 0.75 N/A 1.55 N/A 
Microparticles (drug 
equivalent of 
microparticle) 
N/A 
(N/A) 
10.625  
(0.75) 
N/A 
(N/A) 
21.9  
(1.55) 
Lycoate RS 720 41.125 31.25 N/A N/A 
Glycerin 5 5 N/A N/A 
Tween 80 3.125 3.125 N/A N/A 
Water 50 50 N/A N/A 
Mannitol N/A N/A 93.7 73.6 
Croscarmellose Na N/A N/A 4 4 
Mg stearate N/A N/A 0.75 0.5 
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was then allowed to stand until air bubbles dissipated. Thereafter, this obtained viscous 
sample was casted on a plastic platform using a 6 mm wet film stainless steel bar 
applicator (BYK Inc, CT, USA). The film was dried in a tray oven and was cut into 
multiple pieces of 3×3 cm (9 cm2) with the aid of BYK chart paper. ODT were also 
prepared based on the compositions presented in Table 2-2. Drug contents as well as 
weight of an ODT were pre-calculated based on those of an ODF. All powder ingredients 
were blended and compressed into a biconvex tablet with a diameter of 5.56 mm using a 
Carver hydraulic press (Carver INC, IN, USA).The compression force was kept constant 
at 1.5 kN. 
 
 
2.2.8. Characterization of ODF 
 
2.2.8.1. Weight variation and content uniformity 
 
Six pieces of ODF (3×3 cm) were accurately weighed to evaluate weight 
variations. For content uniformity evaluation, each film (six replicates) were dissolved in 
25 mL of 0.1N HCl solution individually. Consequently, the resulting solutions were 
filtered through a 0.22 µm microporous membrane filter. The drug concentration was 
determined by UV absorbance at 262 nm. 
 
2.2.8.2. Tensile strength 
 
 Tensile strength (tensile stress at break) of ODF was evaluated using dynamic 
mechanical analyzer equipped with a film clamp (TA instrument, DE, USA). A film was 
clipped into the clamp with one side fixed and the other side movable. The dimensions of 
the film were fed into the analyzer. The preloaded force was kept constant at 0.01 N then 
followed by ramping at 0.5 N/min until the film broke.  The temperature was maintained 
at 25 °C during all the experiments and the average tensile strength was calculated based 
on six replicates. 
 
2.2.8.3. In vitro disintegration 
 
In vitro disintegration testing of ODF was performed using the Pharmacopeia 
disintegration apparatus for capsules and tablets (Hanson Research, CA, USA). Each film 
strip was cut into an appropriate size (n=3) and then carefully placed at the bottom of a 
disintegration basket tube. The system was maintained at 37 °C and simulated saliva was 
chosen as the medium. Disintegration time was monitored until the film completely 
disintegrated into fine particles. 
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2.2.9. Characterization of ODT 
 
2.2.9.1. Weight variation and content uniformity 
 
 Six tablets were weighed to determine average weight variation and content 
uniformity, following the same procedures specified in Section 2.2.8.1 (n=6). 
 
2.2.9.2. Tensile strength 
 
Tablet hardness was measured using a manual tablet testing instrument (Vortex 
sales group, NC, USA). Tensile strength was calculated using Equation 2-5: 
 
Tensile strength= 2∗Fd
π∗D∗H    (Eq. 2-5) 
 
Where Fd is tablet hardness, D is tablet diameter, and H is tablet central cylinder thickness. 
 
2.2.9.3. Friability 
 
Friability was performed using a friabilator (Sotax, MA, USA). Twenty tablets of 
each formulation were first de-dusted, weighed and mixed with 3 mm glass beads to 
make a total weight of around 6 g. Tablets and 3 mm glass beads were placed into the 
drum. After 100 revolutions, the tablets were first examined for appearance, and then 
weighed. Percent friability was calculated using Equation 2-6. 
 
Percent Friability=initial  weight −final  weightinitial  weight ×100%  (Eq. 2-6) 
 
2.2.9.4. In vitro disintegration 
 
The procedure for in-vitro disintegration testing was similar to the one specified 
in Section 2.2.8.3. One tablet was cautiously placed in the bottom of a disintegration 
basket tube. The average disintegration time was calculated from three replicates.  
 
 
2.2.10. Drug dissolution from ODF and ODT 
 
 Dissolution tests were conducted at two different dissolution setups. Initially, to 
evaluate drug dissolution in the oral cavity, the USP basket apparatus (Distek INC, NJ, 
USA) was utilized. Three hundred milliliters of simulated saliva (pH=6.8) were 
maintained at 37 °C. One film or tablet was placed inside the basket and immersed in the 
dissolution medium. The rotation speed of the basket was kept at 50 rpm. The 
concentration of Chlorpheniramine Maleate was monitored using an in-line ultraviolet 
detector connected with fiber optic cable at 262 nm (pION, MA, USA).  
 
Thereafter, to evaluate drug dissolution in the stomach, the USP paddle apparatus 
(Distek INC, NJ, USA) was utilized. Nine hundred milliliters of simulated gastric fluid 
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(pH=1.2) were maintained at 37 °C. One film was hanged with a clip or one tablet was 
directly loaded into the vessel. The paddle rotation speed was kept at 50 rpm. Drug 
concentration was analyzed at 262 nm using the same detector. 
 
 
2.2.11. Taste masking evaluation 
 
 Taste masking evaluation was performed using a single blind study according to a 
published design with minor modification.5 The bitterness of two ODFs and two ODTs 
were evaluated: ODF (control drug alone), ODF (coated microparticle), ODT (control 
drug alone), and ODT (coated microparticle). Ten adult volunteers were involved in this 
study. Each individual was asked to place each formulation on his/her tongue for 45 
seconds and give a score based on his/her feelings about intensity of the bitterness. 
Intensity of bitterness was ranked from four numerals 0 to 3, where 0=no bitterness, 
1=slight bitterness, 2=moderate bitterness, and 3=strong bitterness. The average score of 
each formulation should be equal to or less than 1 to be considered acceptable for 
pediatric applications. 
 
 
2.3. Results 
 
 
2.3.1. Drug encapsulation efficiency 
 
Drug encapsulation efficiency is defined as the ratio of the actual amount of 
encapsulated drug to the theoretical amount that was added. This indicator is a vital 
criterion which is used to evaluate the quality of microparticles. It has been illustrated 
that drug encapsulation efficiency could be significantly influenced by many formulation 
and process variables. For example, O’Donnell and McGinity concluded that the 
selection of the organic phase and the volume fraction of the organic and aqueous phases 
affected the encapsulation efficiency and the microparticle porosity.32 They also pointed 
out that the properties and amount of polymers were also influential on the drug 
encapsulation efficiency.32 Additionally, the process variables during the spray drying 
cycle are considered significant factors. In this study, gas flow (Q-flow) at the nozzle tip 
of the spray dryer was selected for further investigation because it controls the dispersion 
process of the spray dried solution into fine liquid droplets, thereby possibly affecting the 
drying process and drug encapsulation efficiency.  
 
Values of drug encapsulation efficiency for all experimental batches were listed in 
Table 2-3. All experimental batches had acceptable encapsulation efficiency values 
which ranged from 60% to 90%. After fitting data to both linear and quadratic models, 
the best-fit polynomial equation was determined as a modified quadratic model as shown 
in Equation 2-7, where the R-square value was 0.98. Analysis of variance (ANOVA) 
indicated that drug encapsulation efficiency was significantly influenced by experimental 
variables. Moreover, all predictor variables introduced in this equation were significant 
variables.  
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Table 2-3. Responses (drug encapsulation efficiency and percentages of drug released) of microparticle formulations. 
 
Formulation % EE Y1h Y2h Y3h Y4h Y8h Y12h Y24h 
1 replica a 70.5 19.6 29.7 35.8 39.0 55.2 69.2 93.1 
1 replica b 70.0 20.7 28.5 34.2 40.2 59.1 72.3 89.6 
2 replica a 74.3 19.6 46.2 56.7 60.5 80.7 89.4 91.0 
2 replica b 71.6 16.7 38.3 45.7 51.9 73.2 87.9 90.1 
3 replica a 62.8 20.8 32.7 41.4 53.2 64.9 75.2 87.5 
3 replica b 59.8 26.3 37.8 43.2 53.5 62.3 71.6 84.6 
4 replica a 86.8 17.5 23.3 25.4 27.4 35.8 42.6 62.3 
4 replica b 87.9 16.6 21.1 24.9 27.8 37.9 46.3 67.6 
5 replica a 81.0 12.7 20.3 23.7 32.4 42.1 49.7 71.2 
5 replica b 81.6 10.9 18.1 24.6 27.5 40.3 50.9 76.6 
6 replica a 73.2 15.7 25.6 27.8 29.8 42.0 52.3 70.1 
6 replica b 70.0 13.9 23.6 28.9 33.9 45.6 56.8 73.5 
7 replica a 84.2 7.0 12.3 14.4 19.3 24.8 30.2 41.7 
7 replica b 84.8 11.0 13.3 14.8 17.6 20.0 28.9 40.5 
8 replica a 71.1 13.9 18.6 22.7 25.4 35.5 42.7 56.0 
8 replica b 69.0 14.0 20.5 24.2 26.9 34.3 40.8 59.9 
9 replica a 69.6 13.8 25.0 31.0 33.6 41.5 47.3 64.4 
9 replica b 69.8 12.0 23.0 28.4 32.7 41.3 48.8 64.1 
 15 
      Drug encapsulation efficiency (%)=-74.50+13.81X1+6.42X2+4.41X3   
+0.98X1X2+0.18X1X3-0.48X2X3-0.81X12   (Eq. 2-7) 
 
 The influence of the three variables on drug encapsulation efficiency was 
schematically represented by three-dimensional surface response plots as seen in  
Figure 2-1. It was observed that drug encapsulation efficiency decreased as 
dichloromethane content increased. This observation may be related to the change in the 
porous nature of microparticle, which was explained by O’Donnell and McGinity.32 In 
addition, Q-flow was positively relevant to drug encapsulation efficiency. During the 
spray drying process, dichloromethane was evaporated in an extremely short period of 
time at a temperature above its boiling point. The hypothetical explanation is that the 
higher Q-flow dispersed the solution into finer droplets and then produced smaller 
microparticles that resulted in higher drug encapsulation efficiency. This result was also 
observed and explained by others where weakly bounded drug molecules on the surface 
of microparticles were more easily removed from larger but less dense particles during 
the preparation process.33 Finally, the drug encapsulation efficiency was also significantly 
influenced by polymer amount; however, as observed in Figure 2-1, this influence was 
parabolic and intertwined by interactions between polymer variable and other variables. 
 
 
2.3.2. In vitro release tests 
 
Percentage of drug release values were listed in Table 2-3. The slowest drug 
release percentage was around 40% at 24 h (Formulation 7) and the highest one was 
around 90% at 24 h (Formulations 1 and 2). Release profiles for all formulations resulted 
in a burst release in the first segment, followed by a zero-order release. This phenomenon 
was explained by Freiberg and Zhu who indicated that initial burst release is caused 
mainly by molecules extracted from microparticle shells, and the second zero-order 
release segment was primarily dependent on molecules diffusing through the matrix.34 
Statistical analysis for the polynomial equations was conducted to determine the 
relationship between drug release and variables (X1, X2, X3). Percentages of drug 
released at predetermined time points were fitted to both linear and quadratic 
mathematical equations. It was noted that although the quadratic model provided an 
equation with a better R-square value, multicollinearity issue may result in insignificance 
and inaccuracy of statistical analysis using this model. Therefore, the linear model was 
chosen for drug release simulation. Linear equations of each time point were described in 
Table 2-4. Analysis of Variance (ANOVA) of all regression equations indicated drug 
release was mainly determined by experimental variable levels. Multiple correlation 
coefficients (R2) which were close to 1 indicated that the developed equations in  
Table 2-4 had a good fit to accurately describe the drug release data. The content and 
composition of polymers are critical for the release of drug from microparticles.35 
 
In our experimental design, the weight ratio of polymer to drug ranged from 5 to 
10 and was the most significant factor. The drug release rate decreased remarkably as 
polymer (Eudragit® EPO) content increased. Our explanation is that drug molecules are 
more difficult to penetrate through the microparticle shell which contains more amounts  
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Figure 2-1. Response surface plot which relates drug encapsulation efficiency (%) 
as a function. 
 
(a) Top: Weight ratio of polymer to drug and volume ratio of dichloromethane to water 
(Q-flow at 37.5 mm); 
(b) Middle: Weight ratio of polymer to drug and Q-flow (volume ratio of 
dichloromethane to water at 5);  
(c) Bottom: volume ratio of dichloromethane to water and Q-flow (weight ratio of 
polymer to drug at 7.5).
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Table 2-4. Optimum regression equations which influenced the percentages of drug released. 
 
Percentage  of 
Drug Release 
Intercept 
Constant (%) 
Coefficient a 
(X1) 
Coefficient b 
(X2) 
Coefficient c 
(X3) 
P-value R-square 
Y1h 30.39 -1.73 0.42 -0.10 0.001 0.68 
Y2h 47.33 -3.35 1.65 -0.13 0.0002 0.74 
Y3h 54.93 -4.05 2.13 -0.13 0.0003 0.73 
Y4h 53.76 -4.76 2.73 0.09 <0.0001 0.80 
Y8h 89.68 -6.60 2.70 -0.19 <0.0001 0.82 
Y12h 110.92 -7.56 2.60 -0.31 <0.0001 0.86 
Y24h 130.06 -6.98 2.06 -0.45 <0.0001 0.90 
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of the polymer and thereby prolonged the release time. Apart from the weight ratio of 
polymer to drug, a faster drug release was achieved as the volume ratio of 
dichloromethane to water increased. This variable was also noticed to have an influence 
on drug release rate by other researchers.36 It is important to note that evaporating a larger 
volume of dichloromethane can possibly result in microparticle shell which is less dense 
and more porous, thereby results in faster drug release. Additionally, the third variable 
(Q-flow) was noticed to have insignificant influence on drug release. 
 
 As a result, microparticles coming from Formulation 7 were selected for loading 
into ODF and ODT for two primary reasons: (1) drug encapsulation efficiency was 
relatively high (around 84%); (2) drug release rate was relatively slow (only around 10% 
released within 1 hour and 40% released within 24 hour). 
 
 
2.3.3. Checkpoint analysis 
 
 Three checkpoints (X1, X2, X3) at three variable levels (10, 3, 37.5) (7.5, 5, 37.5), 
and (8.75, 6, 41.25) were applied to validate the robustness of the developed models. 
Predicted and observed drug encapsulation efficiency values are listed in Table 2-5.The 
predicted drug encapsulation efficiency values of these validated points calculated from 
Equation 2-7 were not significantly different from the actual measured values(P>0.05, 
statistical student t-tests). Predicted and observed drug release profiles were plotted in 
Figure 2-2. All similarity factor (f2) values in Table 2-5 were above 50, which suggest 
good similarity between predicted and observed release profiles. It is clear from these 
results that the values calculated for percentages of drug released according to the 
polynomial model can predict the observed drug release profiles. Moreover, these 
simulated models could also be utilized to predict drug encapsulation efficiency and drug 
release profile for other new untested formulations.  
 
 
2.3.4. Characterization of ODF and ODT 
 
 The ODF and ODT formulations are listed in Table 2-2. The developed ODF 
contains Lycoat as a film forming polymer, glycerin as a plasticizer, Tween 80 as a 
surfactant, and drug (microparticles). Physicochemical and mechanical characterization 
values are listed in Table 2-6. The average weight of ODF control was 87.9±2.4 mg and 
the average weight of ODF with microparticle was 86.3±4.0 mg. Thus, this produced 
films had similar weights whether drug was dissolved in or microparticles were dispersed 
in the casting solvent. Acceptable drug content uniformity was also achieved for both 
ODFs. The average drug content was approximately 1.3 mg, which is suitable strength 
for prescribed pediatric dose of 1 to 2 mg. The drug content and the weight of an ODT 
were aimed to be identical to those of an ODF. Thus, theoretical drug percentage in 
powder blends and in tablet weights were pre-matched. Consequently, the obtained data 
demonstrated that ODT controls and ODT with microparticle had extremely small weight 
variation and uniform drug content which closely matched their theoretical values.  
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Table 2-5. Comparison between the predicted and the actual values for 
encapsulation efficiency and f2 similarity factor testing for the three selected 
variable levels. 
 
Formulation (X1 X2 X3) (10 3 37.5) (7.5 5 37.5) (8.75 6 41.25) 
Predicted EE% 75.1 77.0 72.4 
Observed EE% 74.3±1.5 75.9±1.5 73.8±2.2 
P-value (EE%) 0.48 0.31 0.40 
Similarity factor (f2)  83.8 72.4 76.5 
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Figure 2-2. Predicted and observed release profiles of three validated 
formulations. 
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Table 2-6. Properties of orally disintegrating films and orally disintegrating tablet formulations. 
 
Formulation ODF 
(Control) 
ODF 
(Micropartile) 
ODT 
(Control) 
ODT 
(Microparticle) 
Weight (mg) 87.9±2.4 86.3±4.0 86.2±2.2 86.1±1.7 
Drug content (mg) 1.318±0.040 1.307±0.052 1.315±0.035 1.332±0.0039 
Disintegration (S) 35.3±5.1 36.0±3.6 16.3±1.5 23.7±1.5 
Tensile strength (MPa) 0.85±0.09 0.51±0.09 0.53±0.06 1.00±0.11 
Friability   1.3% 0% 
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Tensile strength is a vital mechanical property for evaluating the strength and 
robustness of ODF and ODT. ODF controls had significantly higher tensile strength than 
ODF with microparticles and therefore ODF controls were more robust. One possible 
explanation is that microparticles dispersed in the film strips may cause some strength. 
Tensile strength of films in this study was relatively lower than films made by other 
groups,8,9 both films kept good integrity during preparation, packaging, and storage 
conditions. On the other hand, ODT tensile strength is expressed as crushing strength. 
Tensile strength of ODT was noted to significantly increase with the addition of 
microparticles which may be due to higher elasticity of copolymer Eudragit® EPO.  
Disintegration testing demonstrated that both ODF and ODT disintegrated quickly. 
Disintegration time between the two ODF formulations was not significantly different 
(P>0.05). However, there was a significant difference between ODF and ODT 
formulations and between the two ODT formulations (P<0.05). Both ODFs disintegrated 
completely within 40 seconds, which is suitable for the orally disintegrating drug delivery 
systems. ODT had a relatively shorter disintegration time due to the inclusion of super-
disintegrant croscarmellose sodium in the formula. The ODT controls disintegrated 
significantly faster than the ODT with microparticles. This result matched their tensile 
strength results. ODT with microparticles exhibited comparable results to the ODT which 
disintegrated within 10 to 30 seconds and had a tensile strength of 1 MPa.37 Friability 
results indicated that ODT with drug microparticles should have adequate robustness 
during package, storage, and transportation. 
 
 
2.3.5. Drug dissolution from ODF and ODT 
 
The taste of solid formulation is relevant to its drug content and its dissolution 
rate. In contrast to conventional taste masking techniques such as artificial flavors and 
sweeteners, a coating layer applied onto drug powders has been verified as a better 
approach to inhibit contact between drug molecules and taste bud sensors.5,6 It has been 
reported that a slow drug release for only few minutes at the initial stage could reduce 
unpleasant sensations associated with bitter taste of drugs.38 Thus, taste masking of 
Chloropheniramine Maleate can be achieved by reducing the initial drug dissolution rate. 
Dissolution profiles for controls and for microparticles in ODF and ODT at different 
media are presented in Figure 2-3. Both ODF and ODT loaded with microparticles, 
dissolved very fast (90% of total drug amount within 2 minutes) in simulated gastric fluid 
(pH=1.2). Hence, drug release was not hindered by microparticles in simulated gastric 
fluid. In contrast, Eudragit® EPO microparticles in either ODF or ODT slowed drug 
release (approximate 40% at 5 minute) in simulated saliva (pH=6.8) significantly (P<0.05) 
as compared to ODF and ODT controls (more than 90% released at 5 minute). The reason 
is that, in simulated saliva, drug molecules in ODF and ODT loaded with microparticles 
needed to diffuse out from Eudragit® EPO microparticle shell. Additionally, in simulated 
saliva, there was no significant difference for drug release from microparticles in either 
ODF or ODT. The initial drug burst release from microparticles was observed in both 
formulations. The burst release is a manifestation of two reasons: (1) The drug is 
hydrophilic (water soluble); (2) Eudragit® EPO is swellable and water permeable at pH 
higher than 5 where the micro-channels that exist within microparticle shells enhance  
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Figure 2-3. Dissolution profiles of Chlorpheniramine Maleate. 
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drug diffusion. Drug dissolution in the simulated saliva was noticed to be more rapid 
under the experimental conditions listed in Section 2.2.11 as compared to those listed in 
Section 2.2.5. Obviously, the dissolution rate was influenced by experimental conditions. 
It is well understood that diffusion is the main mechanism of dissolution under the 
conditions listed in Section 2.2.5 while convection affected the dissolution listed in 
Section 2.2.11. In our study, we selected the conditions listed in Section 2.2.5 rather than 
those listed in Section 2.2.11 to evaluate drug release models of microparticles. It is 
mainly because relatively more experimental deviations among replicates (within same 
formulations) were observed in experiments conducted under the conditions listed in 
Section 2.2.11. Consequently, it became apparent that we would have some difficulty in 
building a precise model for establishing correlation between the variables and responses 
and obtaining optimized microparticle formulations.  
 
 
2.3.6. Taste masking evaluation 
 
 Statistical scores of taste masking evaluations were listed in Table 2-7. In this 
experiment, the drug content in each unit dose was identical for all tested formulations 
(ODF and ODT). The results indicated that microparticles in either ODT or ODF 
successfully alleviated drug bitterness down to an acceptable level (score≤1). ODT with 
microparticles completely masked the bitterness of Chlorpheniramine Maleate(score=0); 
in contrast, slight bitterness (score=1.1) was observed for ODT controls. In addition, 
ODF with microparticle assuaged the intensity of bitterness remarkably from moderate 
(score=2) to slight (score=1). We also noticed that ODT formulations had a better taste 
than ODF Formulations. Perhaps this could be explained by two reasons: (1) the 
excipient mannitol (filler) in ODT has a sweet taste, which could improve the taste of 
ODT; (2) ODF sticks easily on the tongue where released drug molecules and taste buds 
are in contact. This is contrary to ODT since microparticles are swallowed directly after 
disintegration. Therefore, we deduce that taste masking is associated with not only drug 
dissolution, but with other parameters such as the type of the solid dosage form and the 
selection of excipients. 
 
 
2.4. Discussion 
 
It is well known that classical solid oral dosage forms such as tablets or capsules 
are not appropriate for pediatric patients. Thus, alternative formulations are needed to 
enhance patient’s compliance. Our intentions here were to enhance pediatric formulations 
by designing taste masked microparticles of Chlorpheniramine Maleate using Eudragit® 
EPO and incorporate these microparticles in pediatric friendly orally disintegrating film 
and orally disintegrating tablet. Microparticles have been considered a feasible approach 
for taste masking.5,6,39 Unfortunately, this approach has required complicated preparation 
processes as compared to conventional methods for taste masking such as direct addition 
of flavor/sweetener. Despite the complexity of forming microparticles, microparticles 
have several advantages over flavor/sweetener additions particularly when the 
conventional methods are sometimes not effective. This is true when the bitterness 
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Table 2-7. Taste masking evaluation. 
 
Score 
(Bitterness) 
Observation of Individual Numbers (Total Number=10) 
Film  
(Control) 
Film 
(Microparticle) 
ODT  
(Control) 
ODT 
(Microparticle) 
0 (None)  1  10 
1 (Slight) 2 8 9  
2 (Moderate) 6 1 1  
3 (Strong) 2    
Score Average 2 1 1.1 0 
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sensation overpowers the sweetness effect.24 Alternatively, microparticles provide 
practical solution because it inhibits the release of drug on the taste buds. In addition, it 
decreases the amount of excipients needed to mask the taste the bitterness and provide 
more convenient options for formulation scientists. 
 
 In this study, we approached the taste-masking project through optimizing 
experimental variables with the aid of Design of Experiments (DoE). DoE has been 
utilized widely as an organized approach to demonstrate the correlations between 
experimental variables and responses.40 During formulation developments, experimental 
variables can be either material variables (i.e. weight, volume, etc) or process variables 
(i.e. rate, force, etc), while experimental responses can be product quantitative attributes. 
DoE is highly utilized for small-batch formulation development and for scaling-up to 
large-batch processes.40 Since it is quite unreasonable to study all parameters (inputs) and 
all responses (outputs) simultaneously, DoE is generally utilized to optimize key inputs 
and identify key critical outputs. In this study, an orthogonal experimental design L9 (33) 
was introduced to investigate three important variables (the weight ratio of Eudragit® 
EPO to drug, the volume ratio of dichloromethane to water, and Q-flow). Orthogonal 
design, unlike empirical optimization methods, can emphasize the basic and eliminate the 
need for a large number of undesirable experiments.41 As part of the design, we 
correlated key variables and responses using polynomial regression mathematical 
analysis which has been verified as an effective tool to develop formulations.33,42,43,44 The 
results we obtained indicated that polynomial regression can precisely identify the 
relationships between variables and responses and sequentially predict the performance 
of formulations made by same variables at other levels (see Equation 2-7 and Table 2-2). 
This model enabled us to select microparticles from Formulation 7 for further exploration 
due to relatively high drug encapsulation efficiency (around 84%) and slow drug release 
rate (only around 40% released within 24 hour). It is noticeable that the models we 
developed in this study could only be applied for experimental variables under a finite 
range (X1 from 5 to 10, X2 from 3 to 7, X3 from 30 to 45). In addition, the surface 
response analysis cannot satisfy all formulation development requirements (e.g. a large 
number of variables included in formulation process) since polynomial regression might 
not be practical for variables with a high-order dimensionality.45 Thus, in these cases 
artificial neural networks (ANN) is considered as an alternative.45,46 We explored two 
oral dosage forms (ODF and ODT) which are suitable for pediatric patients. Since 
unpleasant taste of the drug has already been attenuated by the formation of 
microparticles, swallowing appropriateness is the other main concern for formulation 
selection. Unfortunately, pediatric patients have difficulty to swallowing regular solid 
dosage forms. And although liquid formulations are acceptable for children; its low 
portability and drug stability may become an issue. On the premise of easy administration 
and swallowing, ODF and ODT are concerned by pharmaceutical scientists.7 
 
 In this study, microparticles were successfully incorporated into both dosage 
forms and the release profile of microparticles did not change significantly as dosage 
forms (ODF or ODT) changed. In terms of acceptable taste-masking efficiency, these two 
dosage forms with microparticle loading could serve as the first front for the oral delivery 
of other bitter drugs for pediatric population. However, although these two dosage forms 
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could both be successfully produced in small batches, there might be challenges for 
future scaling-up and large-batch production. Formulation scientists and process 
engineers might utilize Design of Experiment (DoE) as the key to overcome these 
challenges. 
 
 
2.5. Conclusion 
 
In this study, spray drying method is an appropriate method to produce 
microparticles with expected drug encapsulation efficiency and drug release profile. Drug 
encapsulation efficiency and release profile of microparticles made from various variable 
levels could be predicted accurately and the optimized microparticles were obtained with 
the aid of polynomial equations and response surface plots. The selected microparticles 
were formulated into ODF and ODT with reliable and reproducible preparation processes 
(small variations in weight as well as drug content, acceptable strength). The ODF and 
ODT disintegrated in short period of time, which are qualified for orally disintegrating 
dosage forms. Drug bitterness intensity was alleviated significantly in oral cavity, but 
Eudragit® EPO did not slow drug release in stomach. In conclusion, both ODF and ODT 
containing microparticles are potentially appropriate for pediatric uses.  
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CHAPTER 3.    INFLUENCE OF SELECTED ANIONS ON MILLING OF 
SULFAMERAZINE NANOCRYSTAL﹡ 
 
 
3.1. Introduction 
 
Solid oral dosage forms are user-friendly and therefore preferred over many other 
dosage forms for systemic drug delivery. Typically, a satisfactory oral dosage form 
requires acceptable bioavailability which is related to drug solubility, dissolution, 
permeability and absorption. Unfortunately, many new drug molecules are hydrophobic 
and have low oral bioavailability.47 To overcome this challenge, formulators have made 
significant effort to enhance dissolution rate and solubility of drug molecules, particularly 
those classified in the biopharmaceutics classification system (BCS) as Class II (high 
permeability and low solubility) and Class IV (low permeability and low solubility). By 
far, several approaches to enhance dissolution rate and solubility have been developed. 
These include surfactants,48 amorphilization,49 polymorph transformations,50 
complexation,51 salt formation,52 and self-emulsification drug delivery system 
(SEDDS).53 Considering the current progress of formulation design concept from micro-
size level to nano-size level, nanocrystal technology has been matured and became an 
effective methodology for solubility and dissolution rate improvements.54,55,56,57,58,59,60 In 
contrast to other dissolution rate improvement techniques, nanocrystallization has many 
benefits including no organic solvents involvement, high drug loading efficiency, and 
good reproducibility.54 Improvement of drug dissolution by nanocrystallization relies 
primarily on enlarging particles surface area and enhancing solubility of nanoparticles 
(Noyes-Whitney equation). Currently, there are several techniques for forming 
nanocrystals. In general, these methods can be divided into two main categories: 
“bottom-up” technology and “top-down” technology. The “bottom-up” technology 
includes recrystallizing nanocrystals from super-saturated solutions. Due to inherited 
limitations of “bottom-up” technology such as wide variation in particle size distribution, 
solid state transformation (physical instability), and scale-up difficulty, this technology is 
not widely applied.54 On the other hand, the “top-down” technology which involves 
methods for reducing particle size from micron range is more popular. One of the most 
important “top-down” methods is wet bead milling which is chosen for making 
nanocrystals quite frequently.61 
 
In wet bead milling, drug particles and beads/pearls are milled in an aqueous 
medium and particle size is reduced by intensive collision. Due to higher surface energy, 
nanosuspensions have several folds of magnitude of internal energy as compared to that 
of conventional suspensions. For this reason, a large quantity of stabilizers is required to 
stabilize nanoparticles and either polymers or surfactants are used as stabilizers. During 
the last decade, extensive and significant research has been carried out to evaluate the 
 
 
﹡: Adapted with permission. Lou H, Liu M, Qu W, Johnson J, Brunson E, Almoazen H. 
The influence of sodium salts (iodide, chloride and sulfate) on the formation efficiency of 
sulfamerazine nanocrystals. Pharm Dev Tech. In Press.  
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influence of stabilizers on wet milling. It is recognized that this influence may be caused 
by the amount of stabilizer,62  its molecular weight,63 hydrophobicity/hydrophilicity,62 and 
functional groups.64 Moreover, other milling parameters such as type of drug,62,65 milling 
bead,65,66 milling frequency,67 and milling time67 were investigated.  
 
As far as we know, wet milling has been explored in depth, but certain 
information on few aspects were not explored and are worthy of further investigation. For 
example, different salts (ions) could be dissolved in milling medium and their effects on 
milling efficiency is worth to be explored. The key question is: whether the addition of 
salts would positively or negatively affect milling? It must be noted that the influence of 
several anions on hydrocarbons’ solubility (salting-in and salting-out effects) have been 
studied.68 According to Hofmeister ion series, the ranking of anions were based on the 
ability to increase surface tension of water and decrease the solubility of hydrocarbons in 
water. These anions were ranked as follows: SO42->HPO42->OH->F->Cl->Br->NO3->I-
>SCN-. The anion to the left has the highest salting-out capability (increase surface 
tension and decrease hydrocarbon solubility in water) while anions to the right have the 
highest salting-in capabilities (decrease surface tension and increase hydrocarbon 
solubility in water). Although this phenomenon has been studied and documented, its 
implication on nanosuspension milling has not been studied yet. Briefly, the influence of 
salts is believed to “make” or “break” water structure. However, new theories derived 
from thermodynamic studies stated that the bulk water structure may not be enough 
linked to the effect of Hofmeister ions ranking. Interestingly, few scientists illustrated 
that ions, particularly anions, act directly on the first hydration shell of hydrocarbons and 
the hydrocarbon’s surface tension as well as the ion binding capability.68 The influence of 
anions in the Hofmeister series on hydrocarbon-water system has been applied in 
pharmaceutical development. For example, various salts were selected and utilized to 
prevent particle agglomeration during the coating process69 and to control the drug 
release pattern.70 
 
 The effect of salts as described above led us to hypothesize that wet bead milling 
might be influenced by the addition of salts since polymeric stabilizers play a critical role 
in maintaining drug nanoparticles physical stability. The objective in this study was to 
evaluate the influence of anions (sodium as cation) on nanocrystal formation by wet bead 
milling. Sulfamerazine was chosen as the model drug. Sulfamerazine belongs to the 
family of sulfonamide drugs, which are commonly used as antibacterial agents. 
Sulfamerazine has very limited solubility in water. 
 
 
3.2. Experimental Procedures 
 
 
3.2.1. Materials 
 
 Sulfamerazine were purchased from Sigma Aldrich (MO, USA). Zirconium oxide 
beads (0.5 mm diameter) were purchased from NextAdvance (NY, USA). Trifluoroacetic 
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acid was purchased from Fisher Scientific (PA, USA). Polyvinylpyrrolidone (PVP) K30 
was kindly donated by BASF (NJ, USA). De-ionized water was used in this study. 
 
 
3.2.2. Wet-bead milling 
 
 Wet-bead milling was carried out using a Retsch Ball mill (Model MM200, PA, 
USA). The frequency of vibration was kept constant at 30 Hz and the milling time was 
maintained for 6 hours. One gram of Sulfamerazine, four grams of zirconium oxide beads, 
and five milliliters of milling medium were loaded into a 10 mL stainless steel jar. 
Milling mediums were PVP solutions (1% w/v) with and without salts. Three types of 
salts were studied (sodium iodide, sodium chloride, and sodium sulfate) at three 
concentrations of 0.1 M, 0.5 M, and 1 M. 
 
 
3.2.3. Particle size measurement 
 
 Laser diffractometry (Micromeritics, GA, USA) with DigiSizer5200 software was 
employed to analyze particle size distribution. Sulfamerazine saturated solution was 
chosen as the background solution and powders were dispersed in this solution. Particle 
size was expressed as volume distribution according to the Mie theory. Relative 
refractive index of water (1.33) was included in the calculations used in this experiment. 
 
 
3.2.4. Determination of PVP adsorption on particle surface 
 
 The amount of PVP adsorbed on particle surface was determined by subtracting 
the PVP amount left in the solution after milling from total PVP amount in the initial 
solution (initial solution is 1% PVP solution: 50 mg PVP in 5 mL milling medium 
(theoretical); 49.6 mg PVP in 5 mL milling medium (actual)). All samples were first 
filtered through a 0.22 µm membrane filter. A HPLC system (Shimadzu, Japan) which 
included a solvent delivery module, a vacuum degasser, a column oven, and a diode array 
detector was utilized to determine the amount of PVP in solutions. Aliquots of 10µL of 
filtered samples were injected into a reversed phase C18 column (4 µm, 4.6×150 mm, 
Waters, Ireland). The column temperature was maintained at 35 °C. The mobile phase 
consisted of 0.01% (v/v) trifluoroacetic acid in water was supplied at a flow rate of 0.6 
mL/min. The wavelength for PVP quantification was set at 200 nm. 
 
 
3.2.5. Lyophilization 
 
 After 6-hours of ball milling, 5 mL of suspension was withdrawn from the jar and 
lyophilized at -80 °C and 0.01 mbar for 60 hours (Labconco, KS, USA). Nano-micro 
suspensions milled in medium without salt (Formulation 1) and in medium with 1 M 
sodium sulfate (Formulation 2) were selected for lyophilization and further evaluation. 
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3.2.6. Determination of drug content in lyophilized powder blends 
 
 To evaluate drug content in lyophilized powder blends, Sulfamerazine amounts 
were quantified at 263 nm using a UV spectrometer (PerkinElmer, MA, USA) with 
proper dilution. Briefly, 10 mg of powder blends were dissolved in 100 mL of de-ionized 
water, followed by mechanical shaking overnight. Drug loading was characterized as the 
percentage of drug amount in the powder blend. 
 
 
3.2.7. Powder dissolution tests 
 
 In-vitro powder dissolution tests were performed using a USP paddle apparatus 
(Hanson Research, CA, USA). Briefly, 25 mg of Sulfamerazine powder or powder blend 
equivalents to drug content (lyophilized) were first dispersed in 2 mL of de-ionized water 
with manual shaking. This suspension was prepared in order to break any loose 
agglomerates.  
 
Afterwards, the suspension was loaded to 500 mL of de-ionized water. The 
temperature was maintained at 37 °C. Paddle rotation speed was kept constant at 25 rpm. 
Powders of lyophilized Formulation 1 and Formulation 2 were evaluated for dissolution 
test and conventional Sulfamerazine was utilized as the control. The concentration of 
Sulfamerazine was monitored at 263 nm using a UV spectrophotometer. Three replicates 
were carried out for each sample. 
 
 
3.2.8. Differential scanning calorimetry 
 
 DSC Q2000 (TA Instruments, New Castle, DE, USA) equipped with a nitrogen 
cooler that purge nitrogen gas at 50 mL/min was utilized to explore the thermal behavior 
of the samples. The instrument was calibrated using Indium standard. Four samples 
(approximately 5 mg each) were tested. These included sodium sulfate, conventional 
Sulfamerazine (crystalline), lyophilized powder of Formulation 1, and lyophilized 
powder of Formulation 2. Samples were first sealed in an Aluminum pan. Thereafter, 
samples were heated at 10 °C/min from 25 to 250 °C. 
 
 
3.2.9. Stability tests 
 
 Lyophilized powders from suspensions were stored at 25 °C/65% RH. Particle 
size distribution was analyzed again after one month according to parameters in Section 
3.2.3. 
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3.3. Results 
 
 
3.3.1. Particle size measurement 
 
 It has been reported that wet bead milling is an effective method to reduce particle 
size to the nanometer size.57,58,59,60,61,62,63 In this study, the effect of the anions of various 
sodium salts in the suspension medium on wet milling efficiency was investigated; other 
important parameters such as milling frequency, milling time, amount of drug, amount of 
stabilizer PVP (K30), beads, and medium volume were kept constant. The average 
diameters (d (v, 0.1), d (v, 0.5), and d (v, 0.9)) for 10%, 50%, and 90% of all measured particles 
after milling were plotted in Figure 3-1. Figure 3-1 shows particle diameters for milled 
suspensions without salts, and with 0.1 M, 0.5 M and 1 M of NaI, NaCl and NaSO4 
respectively. Before milling, the particle size distribution of Sulfamerazine powders was 
in the micron range and hardly any particles were in nanometer range since d (v, 0.1) was 
10.1±2.9 µm, d (v, 0.5) was 31.1±0.5 µm, and d (v, 0.9) was 84.1±2.4 µm. After milling, 
Sulfamerazine particle size was reduced significantly and the majority of particles d (v, 0.9) 
was in the lower micron range. Since all the mediums used for milling contained 1% (w/v) 
of PVP, the one which had no salt used as a control. After milling, the d (v, 0.5) was 
1.665±0.101 µm for this control and approximately 20.9% of total volume of powders 
were below 1µm (see first bar in Figure 3-1). The volume percentiles of particles with a 
diameter less than 1 µm were plotted in Figure 3-1b. As can be seen in Figure 3-1b, the 
volume percentile for the majority of particle size distributions for the milled suspensions 
which contained sodium iodide and sodium chloride were below 30% including the      
0.1 M of sodium sulfate suspension. The student t test was utilized to analyze statistical 
significance, the 1 M sodium iodide was not statistically significant as compared to 
control. The 1 M sodium chloride was statistically significant as compared to control 
(p<0.05) and the 1 M sodium sulfate was more statistically significant (p<0.01). 
 
 Although this effect was not very obvious at sodium sulfate concentration of  
0.1 M which showed a d (v, 0.5) value of 1.653±0.024 μm and a volume percentile of 21.2% 
for particles diameters below 1µm, interestingly, the particle reduction became 
significant as sodium sulfate concentrations increased to 0.5 M where (d (v, 0.5) was 
1.285±0.023 μm and the volume percentiles of particles with a diameter below 1µm was 
32.4%. As the sulfate concentration increased to 1 M, the d (v, 0.5) became  
0.934±0.015 μm and the volume percentiles of particles with diameters below 1µm were 
55.3%. According to the classification of Van Eerdenbrugh and coworkers, the milled 
suspension with sodium sulfate (1 M) is Nanosuspension since more than 50% of the 
volume of particles was below 1 µm and d (v, 0.9) was below 2.5 µm.62 
 
A possible explanation for the effect of salts on particle size is related to the tested 
anion which can decrease the stabilizer’s (PVP) solubility in water and consequently 
enhance the adsorption of the stabilizer onto the Sulfamerazine particle surface. 
Nanoparticles typically have higher surface energy as compared to the micron range 
particles and are not thermodynamically stable due to particle aggregation and/or crystal 
growth. To stabilize a nanosuspension, polymeric stabilizers are introduced to stabilize  
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Figure 3-1. Particle size and volume percentiles of particles in suspensions below 
1 µm. 
 
**: p<0.01;  *: p<0.05;  o: no significant difference. 
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the nanoparticles and one of the critical requirements for selection of a stabilizer is its 
ability to adsorb onto drug particle surface.71 Thus, we hypothesize that sulfate ions at 
relatively high concentrations increases the total amount of PVP adsorbed onto particle 
surface, thereby causing more stabilizing influence on nanoparticles stability and 
enhancing the milling efficiency. This effect can be rationalize according to Hofmeister 
ion series where the sulfate ion tends to break the water structure and influence the 
hydration on the Sulfamerazine particle consequently increasing the adsorption of PVP 
onto the particle surface. We have not considered conducting solubility of PVP in salt 
solutions because PVP is freely soluble in water and viscosity becomes a limitation at 
high concentrations. 
 
 
3.3.2. Determination of PVP adsorption on particle surface 
 
 Several scientists illustrated that the adsorption of polymers onto solid surface is 
critical for nanoparticle stabilization by weak interactions such as steric forces.72 Ploehn 
and Russel referred to the adsorption of polymer as a compensation of free energy 
reduction over entropy loss.73 It has also been reported that anions in the Hofmeister 
series have important effect on polymers’ solubility and adsorption onto solid 
surfaces.68,74 Therefore, the quantitative determination of polymer adsorption on particle 
surfaces is an important and efficient approach to validate this assumption. As we 
mentioned, the function of (PVP) during milling is the adsorption onto the surface of the 
drug particle (described in Section 3.3.1). The amounts of PVP adsorbed onto drug 
particle surface were calculated by measuring the depletion of PVP from the medium. 
 
 Adsorption data are listed in Table 3-1. As we observed, anions (sulfate, chloride, 
and iodide) have different influences on PVP adsorption. The total amount of adsorbed 
PVP for control (no salt) was 4.9±2.0 mg/g and 4.8±1.9 mg/m2. It was shown that as 
iodide salt was applied regardless of different concentrations, the total amount of 
adsorbed PVP was negligibly different to that without salt (control). On the other hand, 
chloride and sulfate salts increased PVP adsorption considerably, especially at higher 
concentrations; it was indicated that 12.5±2.5 mg/g PVP was adsorbed with sodium 
chloride (1 M) and 20.2±0.8 mg/g PVP was adsorbed with sodium sulfate (1 M) 
respectively. In view of this, we could lead to a conclusion about the rank of capability of 
anions’ influence on PVP dehydration which is sulfate>chloride>iodide. Moreover, by 
tying these values to particle size values, it is worth suggesting that the stabilization of 
particle size in nanometer level might be partly due to more PVP which covers larger 
surface area of nanometers. Additionally, it is logically hypothesized that more PVP 
molecules consequently have higher steric interaction to stabilize the nanosuspension. 
 
 
3.3.3. Lyophilization 
 
 Spray drying and lyophilization are currently the two most typical methods for 
drying suspensions.74 In this study, we anticipated the circulation of spray dryer would 
easily be clogged by viscous milled suspensions and therefore we decided not to use the  
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Table 3-1. The amounts of PVP adsorbed onto Sulfamerazine particles after 
milling at concentrations. 
 
Milling Medium  
PVP Solution 1%  
(with or without Salt) 
PVP in 
Solution after 
Milling  
(mg) 
PVP Adsorbed onto 
Sulfamerazine 
Particle Surface 
(mg/g) 
No salt 44.7±2.0 4.9±2.0 
Sodium Iodide 0.1 M 45.2±1.3 4.4±1.3 
Sodium Iodide 0.5 M 45.3±1.6 4.3±1.6 
Sodium Iodide 1 M 44.2±0.7 5.4±0.7 
Sodium Chloride 0.1 M 44.0±2.3 5.6±2.3 
Sodium Chloride 0.5 M 39.3±2.8 10.3±2.8 
Sodium Chloride 1 M 37.1±2.5 12.5±2.5 
Sodium Sulfate 0.1 M 42.0±2.1 7.6±2.1 
Sodium Sulfate 0.5 M 37.3±0.9 12.3±0.9 
Sodium Sulfate 1 M 29.4±0.8 20.2±0.8 
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spray dryer; instead, we removed water by lyophilization. We lyophilized two 
suspensions, the first suspension was milled in medium containing no salt  
(Formulation 1); and the second suspensions was milled in medium containing 1 M 
sodium sulfate (Formulation 2) which exhibited the highest percentage of particles in 
nanometer size. After drying, loose agglomerates were observed in both powder blends. 
One explanation for this phenomenon is the existence of capillary forces during drying 
and which could be the factor of nanoparticle agglomeration.75 Moreover, particle size 
measurements indicated that these agglomerates were too loose and broke easily upon re-
dispersion. As shown in Figure 3-2, there were no particle size changes for Formulation 
1: d (v, 0.5)=1.615±0.026 µm and the volume percentiles of particles with a diameter below 
1 µm was 20.8% (after lyophilization); d (v, 0.5): 1.665±0.101 µm; the volume percentiles 
of particles with a diameter below 1 µm: 20.9% (before lyophilization). On the other 
hand, for Formulation 2, after lyophilization, particle size (d (v, 0.5): 1.085±0.127 µm; the 
volume percentiles of particles with a diameter below 1 µm: 45.5%) increased slightly as 
compared to that before lyophilization. Despite a slight increase of particle size during 
drying, particle size of dried powders from suspension Formulation 2 was significantly 
smaller than that of dried powders from suspension Formulation 1.In addition, percentage 
of drug content in lyophilized powder blends was determined. Values are summarized as 
follows: 95.6±4.4% for the sample obtained from the suspension Formulation 1 and 
59.4±3.7% for the sample obtained from the suspension Formulation 2. Student t test 
shows no significant difference of particle percentile below 1 µm for lyophilized 
Formulations 1 and 2 and lyophilized Formulations 1 and 2 after 1 month (p>0.05). 
 
 
3.3.4. Powder dissolution tests 
 
 Van Eerdenbrugh and co-workers indicated that nanoparticle agglomeration 
occurs almost inevitably during drying with no addition of matrix former.74 Therefore, we 
strive to preserve the nanoparticles in loose agglomerates that can break up easily. The 
lyophilized powders of suspension Formulation 1 and suspension Formulation 2 
deaggromerated in water via manual shaking, therefore, all powders were first           
re-dispersed to form suspensions and then dissolution evaluation was performed for 
powders in the suspended state. Moreover, the re-dispersed nanosuspension may be the 
ideal formulation for dosing patients for two reasons: (1) nanoparticle advantages can be 
retained; (2) this formulation can be prepared easily by patients at home on their own. 
 
 The dissolution profiles of conventional crystalline Sulfamerazine powder, the 
lyophilized suspension Formulation 1 (control), and the lyophilized suspension 
Formulation 2 (1 M sodium sulfate) are plotted in Figure 3-3. Typically, particles in 
suspensions dissolve faster than dry powders, especially for hydrophobic materials, since 
wetting process takes time. As expected, the lyophilized Formulation 1 released 86% of 
Sulfamerazine within 5 minutes while the lyophilized Formulation 2 released 95% of 
Sulfamerazine within 5 minutes. Both profiles were significantly faster as compared to 
conventional crystalline Sulfamerazine powder which 67% had released within 5 minutes. 
 
This indicates that wet bead milling is an effective method for dissolution rate  
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Figure 3-2. Particle size and volume percentiles of particles below 1 µm of 
lyophilized formulations. 
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Figure 3-3. Dissolution profiles of Sufamerazine. 
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enhancement of Sulfamerazine. In addition, the difference of dissolution rate between 
powder of lyophilized Formulation 2 and powder of lyophilized Formulation 1 is 
relatively small but still distinguishable. This difference partially attributed to the fact 
that powders of lyophilized Formulation 2 had smaller particle size. Although this 
dissolution tests provided a sound validation to the assumption that nanocrystals leaded to 
higher dissolution rate, the correlation between dissolution and particle size could not be 
established here. 
 
 
3.3.5. Differential scanning calorimetry 
 
 DSC is utilized to characterize crystalline states and phase transitions of solids. It 
has been reported that Sulfamerazine has two polymorphs (I and II) and these two 
polymorphs are enantiotropic polymorphs.76 Zhang et al also revealed that polymorph II 
transforms into polymorph I at 173-175 °C with an endothermic peak, and then 
polymorph I shows a significant endothermic peak and melts at around 240 °C.76 In this 
experiment, to confirm whether there is a phase transformation of Sulfamerazine during 
milling and lyophilization, lyophilized samples were evaluated by DSC. All DSC 
thermograms are shown in Figure 3-4. There was no phase change identified for sodium 
sulfate in the studied range. Clearly, the DSC thermograms indicate that the conventional 
Sulfamerazine exists as polymorph I since it indicates only an endothermic pick at around 
238 °C.76 In addition, both powders of lyophilized Formulation 1 and powders of 
lyophilized Formulation 2 have very similar thermal behavior as conventional 
Sulfamerazine since all samples melted at 235 to 238 °C. Therefore, both powders of 
lyophilized Formulation 1 and lyophilized Formulation 2 exist as polymorph I. We can 
conclude that no polymorphic phase transformations were observed during milling and 
lyophilization processes. 
 
 
3.3.6. Stability 
 
 Agglomerates could be observed in powder blends before and after stability tests. 
These agglomerates could be removed via dispersing in a solution with shaking. Particle 
size analysis revealed that there was no considerable change in particle size distribution 
before samples which underwent 1-month stability test and fresh samples, as shown in 
Figure 3-2. 
 
 
3.4. Discussion 
 
 Polyvinylpyrrolidone (PVP), a commonly-used stabilizer, was chosen and kept 
constant in this study. Our intention is to investigate the influence of various anions in 
Hofmeister series on wet milling. Salts such as sodium sulfate played a significant role on 
increasing nano-microcrystal milling efficiency and were kept in lyophilized powder 
blend.  Therefore, the percentage of excipient (excipient loading) in powder blend is 
worth to be noted. In lyophilized Formulation 2 powder blend, percentage of sodium 
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Figure 3-4. DSC patterns of various powder samples. 
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sulfate was around 39% (w/w) and PVP was less than 3% (w/w). In other words, while 
167 mg of Sulfamerazine needs to be dosed followed by a prescription using this 
formulation, approximately 110 mg of sodium sulfate in the blend was also dosed. It is 
necessary to point out that, at this dose level of sulfate, no considerable adverse effects 
were observed and reported in previous human and animal studies.77 Additionally, this 
study is a representative example of expanding a new application of Hofmeister since 
series salts. Sodium sulfate, in this study, had a “salting-out” effect, which lead to an 
increase of milling efficiency (Formulation 2 with 1 M sodium sulfate, 55.5% of particles 
less than 1 µm vs. Formulation 1 without salt, 20.9% of particles less than 1 µm). 
Oppositely, sometimes “salting-in” effect is pursued and applied. For example, more 
organic solvent can be miscible with aqueous phase with the aid of “salting-in” effect. In 
this scenario, some anions ranking at the right side of Hofmeister series such as Iodide 
may be considered. Since salts in Hofmeister series influence the alignment and quantity 
of hydrocarbons including various amphiphiles at different interfaces (e.g. liquid/liquid, 
liquid/solid, liquid/gas), the potential expansion of its pharmaceutical application is quite 
promising and may encompass multiple fields including liquid formulation production 
(e.g. emulsion, suspension, gel, cosolvent, micelle, protein/peptide formulations) and 
solid dosage form development (e.g. coating, wet milling). This study also indicated that 
nonocrystallization is an effective and stable method for dissolution rate enhancement of 
poorly-water soluble drugs. Moreover, most excipients that enhance the production 
efficiency of nanocrystals are cost-economical and therefore have the potential feasibility 
for large-batch size utilization. Despite the fact that considerable percentage of excipients 
in lyophilized powder blend, drug loading in this product is still generally higher than 
another prevalent drug dissolution enhancement approach: amorphous solid dispersion, in 
which large amounts of excipients are usually necessitated to stabilize drug in amorphous 
state.78,79,80 In light of dissolution enhancement, a new concept which combines these two 
techniques has been developed: amorphous drug nanoparticles. Amorphous drug 
nanoparticles can be produced by some specific “bottom-up” methods, similar as 
nanocrystal “bottom-up” methodology, and eventually dispersed in aqueous phase as an 
amorphous nanosuspension. This novel nano-level formulation, may offer an even higher 
saturated solubility and faster dissolution rate as compared to regular nanocrystals.81 
Unfortunately, instability is a challenging obstacle for this technique’s maturation. As a 
consequence, in amorphous nanosuspension system, it is very likely to form small 
amounts of nucleus and/or crystalline particles, and then crystals keep growing as 
amorphous nanoparticles dissolve simultaneously,81 which results in the lost of 
solubility/dissolution advantage. 
 
 
3.5. Conclusion 
 
 In this study, it was shown that wet bead milling is a successful approach to 
reduce particle size of Sulfamerazine. Sodium sulfate (1 M) in milling medium could 
enhance milling efficiency of drug particles significantly and a higher percentage of 
particles were in nanometer level but other salts had minimal effects compared to control. 
Furthermore, powders after milling and lyophilization processes showed remarkable 
dissolution rate improvement.  
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CHAPTER 4.    DEVELOPMENT OF A COATED MINI-TABLET OF CO-
GRINDED PREDNISONE–NEUSILIN COMPLEX FOR PEDIATRIC USE﹡ 
 
 
4.1. Introduction 
 
 Due to the lack of pediatric formulations, the regulatory agencies have initiated 
continual emphasis on the necessity for developing novel pediatric formulations. In 
response, pharmaceutical companies have developed various novel pediatric formulations 
some of which have already been launched into the market.1 
 
 In general, oral delivery of pediatric drugs is preferred over other delivery routes 
since it is convenient, economical, and user-friendly.1 In this study, we utilized 
Prednisone as a model drug and provided formulation methods for developing an oral 
solid dosage form that can be compatible with pediatric patients. Prednisone is a 
glucocorticoid prodrug which converts to its active metabolite Prednisolone in the liver.82 
For decades, this drug has been involved widely in pediatric therapies. At low doses, 
Prednisone is involved in the treatment of emergency rescues such as acute asthma.83 At 
relatively high doses, Prednisone is prescribed for the treatment of pediatric cancer.84 
Although Prednisone has therapeutic uses for many pediatric diseases, there are several 
challenges that should be addressed with the oral delivery of this drug. These challenges 
include: (1) this drug is sparingly soluble in water and has low bioavailability; any liquid 
formulation must include organic solvents; (2) this drug has low tolerance depending on 
the dose strength and can cause fluctuation in overall absorption; (3) this drug should be 
in a dosage form that could be swallowed readily; (4) this drug is extremely bitter which 
requires better palatability through taste masking. 
 
To improve the dissolution rate of poorly-soluble drugs, a number of approaches 
have been reported including amorphilization,49 nanocrystal,55,85,86 complexation,51 salt 
formation,52 and polymorph transformation.50 Although an amorphous form dissolves 
faster than a crystalline form, amorphous solids retain higher free energy levels which 
cause the solid to become unstable and inherit the tendency to convert to the crystalline 
form. In order to stabilize amorphous molecules during the storage and dissolution 
process, preparing solid dispersion is one approach and various polymers such as PVP, 
PEG or cellulose derivatives have been widely used as dispersants.87,88 In contrast to 
organic polymers, Neusilin can also function as a carrier to keep drug in amorphous 
state.89,90 Neusilin® US2 is a porous granule of amorphous magnesium aluminosilicate 
which retains a tremendous surface area (around 300 m2/g). The surface of Neusilin 
contains a large amount of silanol functional groups which facilitate the formation of 
hydrogen bonds.91,92,93 After cogrinding a drug with Neusilin® US2, an amorphous drug-
Neusilin complex is formed.89,90,94 One possible mechanism for the formation of  
 
 
﹡: Adapted with permission. Lou H, Liu M, Wang L, Mishra SR, Qu W, Johnson J, 
Brunson E, Almoazen H. Development of a mini-tablet of co-grinded prednisone-neusilin 
complex for pediatric use. AAPS PharmSciTech. In Press.  
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amorphous complex is linked to the crystalline structure disruption which is caused by 
force of mechanical shearing during milling then followed by the adherence of 
amorphous pieces into Nuesilin® US2 surfaces by hydrogen bonds or salt bridge 
formation.91 It is well known that Neusilin® US2 is involved in solid dosage form not 
only as an adsorbent but also as a low-toxicity excipient which can increase tablet 
hardness.95 
 
Swallowing ability is critical for pediatric formulations. Regular solid dosage 
forms such as capsules or tablets are unfortunately not suitable for pediatric population 
since essentially children less than 10-year-old are not able to grasp the skills of 
swallowing regular size tablets or capsules. Although granules and powders are suitable 
replacements for tablets or capsules, particle size must be characterized to prevent any 
dose fluctuations. To achieve swallowing appropriateness and good unit dose strength, 
mini-tablet is a suitable candidate. Mini-tablet is defined as a tablet with a diameter less 
than 3 mm.13 A recent study conducted by Thomson et al. illustrated that out of 100 
preschoolers, no one suffered the potential of choke caused by swallowing placebo mini-
tablets and up to 86% of 5-year-old children swallowed mini-tablets successfully.14 
Additionally, the manufacturing procedures of mini-tablets can be scaled-up since mini-
tablets can be compressed by regular tablet press with reproducible sizes, weights, and 
dose strengths.15 
 
If a pharmaceutical compound or an excipient has poor pediatric compliance due 
to unpleasant taste, film coating with a polymer is a realistic solution. For instance, 
Eudragit® EPO is s a taste-masking and moisture protective material which has been 
extensively applied in film coating.29 Since it is a pH-dependent copolymer, it is only 
slightly swellable when the pH is higher than 5 and is completely soluble when the pH is 
lower than 5. Therefore, Eudragit® EPO film coating can be used to achieve taste 
masking in the oral cavity (pH=6.8) while keeping the immediate release characteristics 
for the dosage form in stomach (pH=1.2). 
 
The objective of this study was to develop a novel pediatric formulation for 
Prednisone. In this study, dissolution rate of Prednisone was enhanced after cogrinding 
Prednisone and Neusilin to form an amorphous complex. Moreover, this complex was 
compressed with other excipients into 2 mm diameter mini-tablets. Lastly, Eudragit® 
EPO multiple layers were coated on the mini-tablet for taste-masking purpose. 
 
 
4.2. Experimental Procedures 
 
 
4.2.1. Materials 
 
 Prednisone was purchased from Sigma Aldrich (MO, USA). Neusilin® US2 was 
kindly donated by Fuji Chemicals (NJ, USA). Eudragit® EPO is poly (butyl methacylate-
co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) and was kindly 
donated by Evonik (NJ, USA). Croscarmellose sodium was kindly donated by FMC 
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Biopolymer (PA, USA). Magnesium stearate was kindly donated by Mallinckrodt (MO, 
USA). Silicified microcrystalline cellulose was kindly donated by JRS Pharma (NY, 
USA). 
 
 
4.2.2. Milling 
 
 A Retsch Ball mill (Model MM200, PA, USA), attached with a 25 mL stainless 
steel jar and 5 mm diameter stainless steel ball, was used to grind Prednisone with and 
without Neusilin® US2. The frequency of vibration was kept constant at 4 Hz and the 
milling operation time was maintained for 90 minutes. A 1 gram of Prednisone with 
variable amounts of Neusilin® US2 at various ratios (1:1, 1:3, 1:5, and 1:7) were 
physically mixed and then milled at room temperature. After ball milling, samples were 
transferred to a loosely capped glass vial, and stored in vacuum at room temperature. 
 
 
4.2.3. Differential scanning calorimetry studies 
 
 The thermo behavior of samples were explored using a DSC Q2000 (TA 
Instruments, New Castle, DE, USA) which is equipped with a nitrogen cooler at  
50 mL/min nitrogen purge. The instrument was calibrated using Indium standard. Seven 
samples (about 5 mg each) were tested including Prednisone, Neusilin® US2, 1:1 
Prednisone/Neusilin® US2 physical mixture, and co-ground 1:1, 1:3, 1:5: and 1:7 
Prednisone/Neusilin® US2 complex. Samples were first sealed in an Aluminum pan and 
held at 40 °C for 2 minutes. Thereafter, samples underwent modulated heating rate at  
5 °C/min associated with 0.5 °C modulation amplitude every 40 seconds. The overall 
temperature scan ranged from 40 to 300 °C. 
 
 
4.2.4. X-ray powder diffraction and percent crystallinity 
 
 The X-ray powder diffraction of Prednisone, Neusilin and co-ground 
Prednisone/Neusilin complexes at different ratios were obtained using Bruker AXS D8 
advance diffractometer (Bruker, Germany) which is equipped with a copper anode (target, 
Cu Kα radiation; voltage, 40 kV; current, 30 mA; divergence slit, 3.722 mm; antiscatter 
slit, 3.722 mm; detector slit, 5 mm; Goniometer radius, 300 mm) at ambient temperature. 
A thin layer of powder sample was first laid on a sample holder and then measured at 2θ 
in a continuous range from 3° to 40° with a step size 0.048. The percent crystallinity of 
samples was determined using Eva Software (Bruker). A two phase model was employed 
in the determination of the degree of crystallinity; that is the sample is composed of 
crystals and amorphous and no regions of semi-crystalline organization. Thus, the 
diffraction profile was divided in 2 parts: peaks related to diffraction of crystallites and 
broad region related to the scattering from amorphous phase. The assumption is that the 
areas are proportional to the scattering intensities of crystalline and amorphous phases. 
The percent crystallinity was calculated from the integrated intensities of all crystalline 
peaks and the amorphous region under the diffraction curve. Percent crystallinity of 
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sample is defined as Icrystalline/(Icrystalline+Iamorphous). The contribution to the intensity from 
the amorphous region in the sample was identified by properly adjusting the curvature of 
the background curve. The contribution to the intensity from the crystalline region was 
obtained after subtracting the above background curve from the XRD pattern. 
 
 
4.2.5. Solubility measurements 
 
 Excess amounts of Prednisone or co-ground Prednisone/Neusilin® US2 complex 
(1:7) were dispersed into 30 mL of simulated gastric fluid. The suspensions were placed 
in a mechanical shaker at a constant shaking rate of 50rpm and a constant temperature of 
25 °C. Two milliliters of liquid were withdrawn at each selected time point, filtered 
through a 0.22 µm membrane filter, and diluted to an appropriate ratio using simulated 
gastric fluid. The concentration of Prednisone was determined at 242 nm using UV 
spectrometer (PerkinElmer, MA, USA). Three replicates were carried out for each sample. 
 
 
4.2.6. Particle size measurement 
 
 Laser diffractometry (Micromeritics, GA, USA) was employed to analyze particle 
size distribution. Saturated solution of Prednisone was chosen as the background solution. 
Particle size measurement of suspension containing excess powder blend was performed. 
Three replicates were performed for each sample. Particle size was expressed as volume 
distribution according to the Mie theory. Relative refractive index of water (1.33) was 
inserted in this experiment. 
 
 
4.2.7. Surface area measurement 
 
 The specific surface area of each sample was determined by the gas adsorption 
method according to the BET theory using “Gemini” surface area analyzer 
(Micromeritics, GA, USA). Nitrogen gas was adsorbed to powder surface, and the 
amount adsorbed gas was converted into the surface area of powder. Analysis was 
performed at five relative pressures ranging from 0.05 to 0.2. 
 
 
4.2.8. Morphology 
 
 Morphologies of Prednisone, Neusilin, and co-ground 1:7 Prednisone/Neuislin, 
were characterized using the Environmental Scanning Electron Microscope (Philips, 
Netherland) equipped with a Peltier stage. Prior to microscope observation, all samples 
underwent platinum sputter-coating in argon. 
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4.2.9. Core mini-tablet preparation 
 
 Three core mini-tablet formulations were prepared. Formulation 1 was directly 
compressed from a powder blend of (75.2%) co-ground 1:7 Prednisone/Neusilin complex 
containing (9.4%) Prednisone, (18.8%) silicified microcrystalline cellulose, (5%) 
croscarmellose sodium, and (1%) magnesium stearate. Formulations 2 and 3 were 
prepared as control groups. In Formulation 2, drug and excipients were identical to  
Formulation 1, except for the use of 1:7 Prednisone/Neusilin physical mixtures. In 
Formulation 3, no Neusilin granules were added; thus (9.4%) Prednisone was blended 
and compressed with (84.6%) silicified microcrystalline cellulose, (5%) croscarmellose 
sodium, and (1%) magnesium stearate. All mini-tablets were compressed into a biconvex 
tablet with a diameter of 2 mm using a Carver hydraulic press (Carver INC, IN, 
USA).The compression force was kept constant at 125 lb. 
 
 
4.2.10. Characterization of core mini-tablets 
 
4.2.10.1. Thickness, weight variation and unit dose strength 
 
 Thickness of ten core mini-tablets for each formulation (Formulation 1, 2 and 3) 
was determined using a vernier capiler. Weight variation was evaluated by weighing 
mini-tablets (n=10). 
 
 To evaluate unit dose strength, ten core mini-tablets of each formulation were also 
utilized. Briefly, each mini-tablet was dissolved in 25 mL of solution containing water 
(68.8%), tetrahydrofuran (25.0%), and methanol (6.2%), followed by mechanical shaking 
overnight to dissolve all Prednisone. The suspension was then filtered through a 0.45 µm 
filter membrane, and the concentration of Prednisone was determined at 242 nm using 
UV spectrophotometer. 
 
4.2.10.2. Tensile strength and friability 
 
 Tensile strength and friability of mini-tablets (Formulation 1) were conducted. 
Tensile strength was calculated using the following Equation 4-1: 
 
Tensile strength= 2∗Fd
π∗D∗H    (Eq. 4-1) 
 
Where Fd is tablet hardness, D is tablet diameter, and H is tablet central cylinder thickness. 
Tablet hardness was determined using a manual tablet testing instrument (Vortex sales 
group, NC, USA). 
 
 Friability tests were conducted using a friabilator (Sotax, MA, USA). Twenty 
mini-tablets were first de-dusted, weighed, and laid into the friabilator drum with around 
6 gram of 3 mm glass beads. One hundred revolutions were set. Friability was calculated 
according to the following Equation 4-2. 
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Percent Friability=initial  weight −final  weightinitial  weight ×100%  (Eq. 4-2) 
 
 
4.2.11. Core mini-tablet coating 
 
 Due to the small mini-tablet size, mini-tablets could not be coated by fluid bed or 
pan coating. Alternatively, dip-coating process was utilized to coat mini-tablets. A 
coating solution consisted of Eudragit® EPO dissolved in acetone (20%, w/w) was 
utilized for coating. The mini-tablets (Formulation 1) were dipped in Eudragit® EPO 
solution for approximately 40 seconds and then air dried. Thereafter, a 15-second dip-
coating process followed by air-drying was repeated 8 times. This group of coated mini-
tablets was defined as Formulation 4. All coated mini-tablets were dried and stored in a 
vacuum oven at room temperature. 
 
 
4.2.12. Physical stability tests 
 
 The purpose of this study is to examine the influence of moisture on the physical 
stability of Prednisone in the amorphous state over 4 week period. In this experiment, 
core mini-tablets (Formulation 1) and coated mini-tablets (Formulation 4) were stored in 
isolated desiccators at 75% RH (supersaturated sodium chloride solution) in a 25 °C oven. 
 
 
4.2.13. Powder and mini-tablet dissolution tests 
 
 In-vitro powder dissolution tests were performed using the USP paddle apparatus 
(Distek INC, NJ, USA). Five hundred milliliters of simulated gastric fluid (sodium 
chloride 2 g/L; pH adjusted to 1.2 with hydrochloric acid) was maintained at 37 °C. 
Paddle rotation speed was kept constant at 50 rpm. Briefly, 10 mg of Prednisone powder 
or drug content equivalent to Prednisone/Neusilin complex was uniformly sprinkled to 
the surface of the dissolution medium. Co-ground Prednisone/Neusilin complexes at 
different ratios were evaluated and conventional Prednisone was utilized as the control 
group. The concentration of Prednisone was monitored at 242 nm using an in-line fiber 
optic cable connected to ultraviolet detector (pION, MA, USA).  Three replicates were 
carried out for each formulation. 
 
 Dissolution test parameters of core mini-tablets were kept constant as previous 
powder dissolutions. Eighteen mini-tablets (equivalent to 10 mg of Prednisone) were 
directly dropped into the dissolution vessel. Three formulations (Formulations 1, 2, and 3) 
were evaluated and three replicates were carried out for each formulation. 
 
 Dissolution behavior of coated mini-tablets (Formulation 4) was evaluated in 
simulated gastric fluid (pH=1.2) as well as in simulated saliva (pH=6.8). In addition, 
dissolution rates of mini-tablets (Formulation 1 and Formulation 4) after stability test 
were evaluated in gastric fluid (pH=1.2). Dissolution parameters (temperature, paddle 
rotation speed, medium volume, and number of tablets) were kept identical to those of 
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core mini-tablets. Three replicates were carried out for each formulation. 
 
 The dissolution profile similarity factor (f2), as shown in the following  
Equation 4-3, was utilized to compare the dissolution profiles of mini-tablets before 
stability test in Section 4.2.12 and after stability test. 
 
f2=50×log{[1+(1/n)∑ (Rt − Tt)𝑛𝑛𝑡𝑡=1 2]-0.5×100}  (Eq. 4-3) 
 
Where (n) is the number of time points (10 time points, over 60 minutes), Rt is the mean 
percentage of drug released for 1st curve at tt time point, Tt is the mean percentage of drug 
release for 2nd curve at tt time point. Two dissolution profiles are considered similar if 
f2≥50. 
 
 
4.3. Results and Discussion 
 
 
4.3.1. Differential scanning calorimetry studies 
 
 DSC is utilized to evaluate thermal behavior and phase transitions of solids. It 
provides useful information about the solid state properties (crystalline or amorphous) of 
solid materials. All DSC thermograms are shown in Figure 4-1. Conventional Prednisone 
thermogram shows an endothermic sharp peak at 235 °C. This refers to Prednisone 
melting point and also suggests that Prednisone is in crystalline state. On the other hand, 
Neusilin has no melting peak which is indicative of its amorphous state. Previous reports 
in the literature showed that mixing Neusilin with volatile crystalline organic compounds 
may transform these compounds from crystalline state into amorphous state.96 However, 
the 1:1 physical mixture of Prednisone and Neusilin did not show considerable phase 
transformation. Actually, the 1:1 Prednisone/Neusilin physical mixture showed an 
endothermic peak at around 225 °C which indicates that Prednisone maintained some 
crystallinity. We also noticed a shift in melting peaks for 1:1 physical mixture and  
co-ground. This melting point reduction is linked to the interaction between Prednisone 
and Neusilin. In a physical mixture, the addition of Neusilin attracts Prednisone crystal 
aggregates and slightly lowers the melting point of Prednisone. In a co-ground mixture, 
Neusilin and Prednisone have closer interaction since some of the aggregates may have 
smaller size due to grinding and therefore Prednisone melting peak shifts to a lower 
melting point. Hence, the heat of melting of 1:1 physical mixture of Prednisone and 
Neusilin was 31.13 J/g and decreased to 25.13 J/g for 1:1 co-ground mixture. This 
suggests a small reduction in crystallinity. It is likely that only a certain amount of 
Prednisone could exist in amorphous state at 1:1 ratio, and the rest exists as small crystals 
after milling due to insufficient Neusilin adsorption surface. As the amount of Neusilin 
increases, the DSC curves of 1:3, 1:5, and 1:7 complexes show a complete disappearance 
of Prednisone endothermic peak. Thus, further addition of Neusilin caused major 
reduction in drug crystallinity. It was observed that when the content of Neusilin became 
three times in magnitude the drug content or even higher (co-ground 1:3 
Prednisone/Neusilin complex), the majority of Prednisone stays in amorphous state.  
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Figure 4-1. DSC patterns of various powder samples. 
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Therefore, we reach a conclusion that amorphization of Prednisone was related to 
the amount of Neusilin. A possible explanation for this phenomenon suggests that as the 
total surface area of Neusilin® US2 increases, disrupted Prednisone slices would adhere 
and settle onto the surface of Neusilin® US2 granules, thus inhibiting the reversion back 
to the ordered crystalline structure.91 
 
 
4.3.2. X-ray powder diffraction 
 
 Solids in crystalline state have intensive constructive reflections; however, those 
in amorphous state do not reflect X-ray beam since they do not have long-range 
molecular arrangement. The X-ray powder diffraction of conventional Prednisone and 
Prednisone/Neusilin complexes at different ratios are shown in Figure 4-2. The X-ray 
diffraction of Neusilin shows the absence of any peaks which exhibits the amorphous 
nature of Neusilin. Prednisone reveals multiple diffraction peaks including two 
predominantly split peaks at 14° and one peak at 18° as well as other minor peaks 
(percent crystallinity: 86.9). Both the 1:1 physical mixture and co-ground complexes 
indicate similar diffraction characteristics similar to conventional Prednisone. Moreover, 
and as expected, the intensity of X-ray diffraction of 1:1 co-ground complex was slightly 
smaller than that of 1:1 physical mixture. As the amount of Neusilin increased, all 
intensities of characteristic peaks decreased remarkably. When the ratio of Prednisone to 
Neusilin increased to 1:7, the two predominant split peaks at 14° and the one at 18° were 
extremely low in intensity and all other minor peaks completely disappeared (percent 
crystallinity: 25.1). Therefore, the X-ray diffraction suggested that most Prednisone in co-
ground 1:7 complex was in amorphous state. We are led to the conclusion that the 
increase in the amount of Neusilin reduced the crystallinity of Prednisone which was 
consistent with previous DSC results. 
 
 
4.3.3. Solubility measurements 
 
 According to previous literature, the solubility and dissolution rate enhancement 
of drug in amorphous state is caused by the formation of disordered structure of 
molecules which has more free energy as compared to the molecules in ordered 
crystalline structure.97 The solubility of conventional Prednisone and co-ground 1:7 
Prednisone/Neusilin complex were evaluated as a function of time in Figure 4-3. 
Prednisone exists in the crystalline state with highly hydrophobic properties. Figure 4-3 
showed that crystalline Prednisone reached an equilibrium solubility of 0.117 mg/mL 
within 3 hours then held a plateau for up to 72 hours. As for co-ground 1:7 
Prednisone/Neusilin complex, Prednisone reached a maximal solubility at 0.28 mg/mL 
within 10 hours then plateaued for 72 hours. It was obvious that Prednisone/Neusilin 
complex displayed about two folds increase in solubility. Therefore, an amorphous 
Prednisone in the presence of Neusllin, could form a saturated solution and maintain 
solubility for at least 72 hours under this experimental condition. Additionally, solubility 
reduction was not observed in this experiment, which indicated that Neusilin granule may 
be an inhibitor for reducing the recrystallization of Prednisone in saturated solutions.   
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Figure 4-2. X-ray powder diffraction patterns of various Prednisone powder 
samples. 
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Figure 4-3. Kinetic solubility of Prednisone powder samples. 
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4.3.4. Surface area and particle size measurements 
 
 It has been reported that the silanol groups which are situated on the surface of 
Neusilin granules act as potential hydrogen bond acceptors.91,92 Therefore, it is likely to 
form hydrogen bonds between Prednisone and silanol groups. Based on this assumption, 
amorphous Prednisone was expected to adsorb onto the surface of Neusilin® US2. 
According to the literature, by combining the results of surface area and particle size 
analysis, the modality of the drug as either adsorbed to Neusilin surface or kept free in 
the crystal form in addition to the state of Neusilin granule could be evaluated.90 Results 
of particle size and surface area measurements were listed in Table 4-1. The 
manufacturer of Neusilin® US2 reported that the mean particle size ranged from 60 to 
120 µm and the specific surface area of 300 m2/g. This was consistent with the 
experimental values that we obtained milled Neusilin® US2 (mean particle size  
88.62 µm; surface area 329.60 m2/g). Hence, Neusilin® US2 granule was intact without 
fracture or breakage during the milling process under this shaking frequency. The high 
surface area of Neusilin is related to its porous nature and the exposed surface. 
Prednisone crystals had smaller mean particle size of 6.36 µm and surface area of  
3.31 m2/g. To further clarify Prednisone adsorption to Neusilin, we need to pinpoint that 
Prednisone crystals were disrupted during ball milling and slices of Prednisone in the 
amorphous form were adsorbed to Neusilin. Thus, the particle size distribution of  
co-ground Prednisone/Neusilin complex was expected to be similar to that of Neusilin 
granule alone. On the other hand, the surface area of the complex was lower than that of 
Neusilin granules because Prednisone slices covered and/or occupied the surfaces of 
Neusilin. Mean particle size values of co-ground 1:7 Prednisone/Neusilin complex was 
87.74 µm and total surface area was 271.79 m2/g. Therefore, this explains the particle 
size distribution and the lower surface area of Prednisone as compared to those of 
Neusilin. It was noted that as the content of Neusilin in the complex decreased, particle 
size distribution D10, D50, D90, and Mv shifted to smaller values. This in part is due to the 
existence of drug crystals in 1:1 complex (mean particle size: 66.67 µm) and 1:3 complex 
(mean particle size: 75.95 µm). Moreover, the decrease of Neusilin content in the 
complex resulted in a decrease in surface area; e.g. 1:1 complex (surface area:  
157.15 m2/g); 1:3 complex (surface area: 229.04 m2/g). These surface area values could 
be reasoned by (a) drug crystals that remained in the complex after co-grinding had 
relatively smaller surface area; and (b) porous surface on the Neusilin were covered by 
amorphous drug so that surface area was further decreased. 
 
 
4.3.5. Morphology 
 
 The morphologies of Prednisone and Neusilin were directly visualized by 
Scanning Electron Microscope (SEM). This experiment enabled us to observe the 
adsorption of Prednisone to Neusilin surfaces. As seen in Figure 4-4, after cogrinding 
(ball milling), Neusilin® US2 granules were kept intact. It could be seen that Neusilin 
granules had a spherical shape and wide particle size distribution as was also verified by 
particle size measurement using laser diffraction. In addition, the surfaces of granules 
were not smooth, rather porous. 
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Table 4-1. Surface area and particle size analysis of various powder samples. 
 
Sample D10 (µm) D50 (µm) D90 (µm) Mv (µm) Surface Area (m2/g) 
Prednisone 1.44 4.83 12.12 6.36 3.31 
Co-grinded 1:1 D/N 5.71 54.14 144.05 66.67 157.15 
Co-grinded 1:3 D/N 11.44 78.48 144.06 75.95 229.04 
Co-grinded 1:5 D/N 16.16 88.81 158.59 83.29 252.07 
Co-grinded 1:7 D/N 33.24 90.85 160.58 87.74 271.79 
Milled Neusilin® 34.16 90.89 161.63 88.62 329.60 
 
D/N: Drug/Neusilin Complex. 
 
 
 
 
 
 
 
Figure 4-4. SEM micrographs of Prednisone powder samples. 
 
(a) Neusilin; (b) Prednisone; (c) Co-grinded 1:7 drug/Neusilin complex. 
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 It was noted the crystals had a smaller size as compared to Neusilin granules. The 
particle size of Prednisone as obtained by SEM was less than 10 µm. This is consistent 
with the previous particle size measurement. The morphology of co-ground 1:7 complex 
is shown in Figure 4-4. We noticed that most Prednisone particles were adsorbed onto 
the surface of Neusilin and only some particles were left free. This observation verified 
our assumption that Neusilin functioned as an adsorbent that enabled the amorphization 
of Prednisone. It was also observed that the porous surface of Neusilin was partially 
covered by Prednisone particles which were responsible for surface area reduction of 
Neusilin granule. Finally we need to mention that Neusilin maintained its original 
spherical shape and size after grinding. 
 
 
4.3.6. Characterization of core mini-tablets 
 
 The three mini-tablet formulations which were prepared are shown in Table 4-2. 
The unit dose of Prednisone in each tablet was about 0.5 mg which was therapeutically 
appropriate for pediatric indications. Tablet thickness, total weight, and drug content 
were consistent among the three formulations which suggest that single compression 
maintained constant mini-tablet characteristics during the compression process.  In 
addition, results of tensile strength (4.01±0.31 MPa) and friability tests (0.21%) indicated 
that mini-tablets of Formulation 1 containing co-ground 1:7 Prednisone/Neusilin complex 
had acceptable mechanical properties. 
 
 
4.3.7. Powder and core mini-tablet dissolution profiles 
 
 Dissolution profiles of co-ground Prednisone/Neusilin complexes at different 
ratios of 1:1, 1:3, 1:5, 1:7 and conventional (crystalline) Prednisone are shown in  
Figure 4-5. The dissolution profile of crystalline Prednisone (control) indicated that up to 
30% of the drug had dissolved within 20 minutes and around 70% dissolved within 90 
minutes. It is worth mentioning from these results that the amounts dissolved were related 
to the weight ratio of Prednisone to Neusilin. 
 
 The observed differences in dissolution rates were related to the co-existence of 
amorphous and crystalline forms of Prednisone. At the low ratio of Prednisone in the 
complexes (i.e. a ratio of 1:7), more amorphous form resulted in faster dissolution rate. 
This was consistent with the observations of other researchers who investigated 
dissolution rate enhancement caused by different ratios of drug to excipient.98,99 As the 
Neusilin ratio decreased, more Prednisone is present in the crystalline state and less 
amorphous form is adsorbed onto the surface of Neusilin granules which leads to slower 
dissolution rate. Moreover, it is important to mention that incomplete release of 
amorphous form may also be related to the formation of gel-like mass, which was 
discussed by Law and co-workers.100 In order to prepare mini-tablets, and since powder 
complex ratio at 1:7 exhibited the fastest dissolution profile as shown in Figure 4-5, a co-
ground Prednisone to Neusilin complex at 1:7 was selected for mini-tablet (Formulation 
1). In addition, physical mixture at the same ratio and crystalline Prednisone mini-tablets 
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Table 4-2. Characteristics of mini-tablets. 
 
 Formulation Thickness 
(mm) 
 Weight 
(mg) 
Unit Dose 
Strength (mg) 
Tensile Strength 
(MPa) 
Friability 
(%) 
1 1.93±0.03 5.23±0.14 0.55±0.01 4.01±0.31 0.21 
2 1.92±0.01 5.23±0.19 0.54±0.01 NA NA 
3 1.84±0.01 5.40±0.25 0.56±0.01 NA NA 
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Figure 4-5. Dissolution profiles of Prednisone powder samples. 
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were also utilized as controls (Formulations 2 and 3). 
 
 The dissolution profiles of the three mini-tablets (Formulations 1, 2 and 3) which 
were described are shown in Figure 4-6. The mini-tablets dissolution profiles in  
Figure 4-6 show that 1:7 co-ground Prednisone/Neusilin tablets exhibited the fastest 
dissolution profile (87% in 20 minutes) followed by 1:7 physical mixture (68% in 20 
minutes) then the mini tablet with crystalline Prednisone (60% in 20 minutes). Previous 
reports indicated that the disintegration time can positively influence the dissolution rate 
of the drug from tablets.101 Therefore, mini-tablets are expected to disintegrate within a 
short period of time in order to release Prednisone rapidly in gastric fluids. The presence 
of Neusilin in the formulation improves the hardness and may cause a delay to the 
disintegration process. In order to obtain a reasonable disintegration time, croscarmellose 
sodium was added as a super-disintegrant. The dissolution profiles presented in  
Figure 4-6 indicates that disintegration of mini-tablets was acceptable and did not inhibit 
the dissolution rate of Prednisone. It is important to mention that crystalline form of 
Prednisone in Formulations 2 and 3 dissolved much faster as compared to Prednisone 
powders particularly during the initial stage. A possible explanation is linked to the 
hydrophilic properties of the co-blended excipients which include silicified 
microcrystalline cellulose and/or Neusilin. Both can enhance the wettability of 
Prednisone powder. We can conclude from Figure 4-6 that Formulation 1 showed an 
enhanced dissolution rate of Prednisone; therefore it is reasonable to say that Prednisone 
remained in amorphous state during mini-tablet preparation and dissolution processes. 
 
 
4.3.8. Coated mini-tablets dissolution profiles 
 
 Film coating of tablets is a widespread approach to inhibit contact between a drug 
with unpleasant-taste and sensors of taste buds. It was reported that suppression of drug 
release for only few minutes at the initial stage could reduce unpleasant sensations 
associated with bitter taste of drugs.102 Eudragit® EPO, a pH-dependent copolymer, is 
insoluble at pH above 5 but becomes soluble at pH below 5. Therefore, this polymer has 
been selected as an appropriate material for taste masking purpose.29,103 Figure 4-7 shows 
release behavior of Prednisone within coated mini-tablet in both simulated saliva solution 
(pH=6.8) and in simulated gastric fluid solution (pH=1.2). It was observed that when 
coated mini-tablets were placed in simulated saliva, the shape of the tablets was 
unchanged for approximately 70 to 90 seconds then afterwards gel-like flocculants were 
formed. Hypothetically, this may be due to the incomplete disintegration of coated mini-
tablets after water penetration across Eudragit® EPO coating layer. The dissolution 
profile of coated mini-tablet in simulated saliva confirmed the assumption that Eudragit® 
EPO coating layer suppressed Prednisone release significantly (2% within 2.5 minutes). 
However, in simulated gastric fluid, Eudragit® EPO dissolved rapidly and Prednisone 
has dissolved with no barrier. 
 
It is well known that exposure to moisture accelerates the re-crystallization 
process of amorphous drugs and reduces the drug dissolution rate.104 Eudragit® EPO 
coating has been noted to protect against moisture penetration.29 It is expected in this 
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Figure 4-6. Dissolution profiles of core mini-tablets. 
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Figure 4-7. Dissolution profiles of coated mini-tablets. 
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study that it would decrease the moisture uptake of amorphous Prednisone, thereby 
decreasing the re-crystallization process. Drug release behavior of Formulations 1 and 4 
(after 1 month of physical stability evaluation) in simulated gastric fluid were plotted and 
shown in Figure 4-8. The similarity factor value (f2) was calculated and a comparison 
was made between the release profile of fresh coated mini-tablets (Formulation 4), and 
coated mini-tablets (Formulation 4) after one month on physical stability (the f2 value 
was 66.5). Also, a comparison was made between release profiles of fresh core mini-
tablets (Formulation 1) and core mini-tablets (Formulation 1) after one month on physical 
stability, (the f2 value was 46.6).In addition, a comparison was made between release 
profiles of coated mini-tablets (Formulation 4) after one month on physical stability and 
core mini-tablets (Formulation 1) after one month of physical stability (the f2 value was 
70.7) respectively. 
 
 These values indicate that although there is no significant difference between drug 
release profiles for coated and uncoated mini-tablets after 1-month of stability testing, 
Eudragit® EPO coating had some influence on maintaining (moisture decreases 
dissolution rate and therefore coating helps to maintain dissolution rate) drug dissolution 
rate. A possible reason is that Eudragit® EPO coating somewhat decreased the exposure 
of drug to moisture, which can minimize the drug re-crystallization; however, it was 
concluded that re-crystallization of amorphous drug could not totally be inhibited by the 
Eudragit® EPO coating during this limited time frame of 4 weeks. We like to show a 
visual comparison in size between Formulations 1 and Formulation 4 (see Figure 4-9). 
 
 
4.4. Conclusion 
 
 This study demonstrated that co-ground Prednisone-Neusilin complex enhanced 
drug dissolution rate due to a decrease in Prednisone crystallinity. Co-ground Prednisone-
Neusilin (1:7) complex yielded reliable and reproducible preparation processes for mini-
tablets. Eudragit® EPO coating (taste masking) suppressed the drug release from mini-
tablets in simulated saliva (pH=6.8) while maintained immediate release properties in 
simulated gastric media (pH=1.2). Thus, due to its small size, coated and uncoated mini-
tablets of co-ground Prednisone-Neusilin can potentially be appropriate for pediatric use. 
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Figure 4-8. Dissolution profiles of mini-tablets after 1-month stability test. 
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Figure 4-9. Photos of Formulation 1 and Formulation 4. 
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CHAPTER 5.    DEVELOPMENT OF W/O MICROEMULSION FOR 
TRANSDERMAL DELIVERY OF IODIDE IONS﹡ 
 
 
5.1. Introduction 
 
Iodide is vital for the biosynthesis of thyroid hormones triiodothyronine (T3) and 
thyroxine (T4) in the thyroid gland. The deficiency of T3 and T4 leads to thyroid tissue 
enlargement and other metabolic and physiological problems. It has been illustrated by 
previous studies that iodide is massively accumulated in the thyroid gland regardless of 
the dosing route.105,106 This accumulation is regulated by sodium-iodide symporter which 
transports iodide from blood into thyroid epithelial cells.107,108 Typically, small amount of 
iodide is used as a daily nutritional supplement to prevent iodine deficiency,109 whereas 
much larger doses are used to avoid thyroid uptake of radioactive iodide following 
nuclear fission accidents.110,111 Iodide is present in the typical diet, primarily through the 
use of iodized table salt. Oral iodide can also be supplemented as potassium iodide 
(available in both tablet and solution dosage forms) as well as with iodine strong solution 
(Lugol’s solution). However, oral administration may not be ideal in certain populations 
at greatest risk for iodine deficiency, such as infants or patients who suffered surgical 
removal of GI tract. For this reason, transdermal drug delivery system may be an 
appropriate alternative to oral delivery, particularly when oral absorption is compromised 
in disease states characterized by malabsorption (e.g., short bowel syndrome). In contrast 
to other drug delivery systems, transdermal administration offers advantages including 
convenient, non-invasive, and continuous dosing and the avoidance of first-pass 
metabolism.112 
 
It is well understood that low molecular weight hydrophilic compounds including 
ionized compounds can permeate through skin by appendage shunt pathways such as hair 
follicles and sweat glands.113,114,115 However, the total amount of drug which can be 
diffused via this route is limited because of its small surface area compared to the total 
skin. In addition, it has been proposed that small ions can diffuse through lipid bilayer of 
the stratum corneum by the “aqueous” or the “pore” pathway model.116,117,118 In this 
model, pores are formed as a result of defects or imperfections in the interior structure of 
lipid bilayer which leads ions to travel through more rigid tortuous routes.119,120 
Depending on this model, ion diffusion through stratum corneum can be improved by 
altering the porosity of lipid bilayer. Various types of penetration enhancers, such as 
water, surfactants, fatty acids, and azones, can effectively influence the porosity of the 
stratum corneum and further lower its resistance to chemicals.23 On the other hand, ion 
penetration through the skin is also influenced by ion’s permeability. A recent report 
demonstrated that anions have a faster diffusion rate than cations due to the presence of 
negatively charged phospholipid groups in the stratum corneum.121 These findings 
 
 
﹡: Adapted with permission. Lou H, Ni Q, Crill C, Helms R, Almoazen H. Development 
of W/O microemulsion for transdermal delivery of iodide ions. AAPS PharmSciTech 
2013;14:168-76.  
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support our intent to deliver iodide ions through microemulsions. Microemulsion is a 
multicomponent system composed of water, oil, surfactant, and cosurfactant.21 It has been 
intensively utilized as a transdermal delivery system with several advantages including 
low cost and simple preparation, long term product stability, and main ingredients acting 
as solubilization and permeation enhancers.20,22,122 Microemulsion can potentially change 
the internal structure of the lipid bilayer in the stratum corneum and enhance compound 
penetration. Our aim is to develop an iodide transdermal delivery system which has 
potential therapeutic uses when oral administration is not appropriate. In this study, a 
W/O microemulsion system with potassium iodide (KI) was developed. Several 
physicochemical characterizations were conducted to evaluate the system (e.g. pH, 
droplet size, conductivity, viscosity, and stability). Franz diffusion cells were also utilized 
to evaluate the penetration of the iodide ions through human skin. 
 
 
5.2. Experimental Procedures 
 
 
5.2.1. Materials 
 
 Potassium iodide (KI), Span 20 and Pyrene were purchased from Sigma Aldrich 
(St. Louis, MO, USA). Anhydrous ethanol was purchased from Fisher Scientific (Thermo 
Fisher Scientific Inc, Pittsburgh, PA, USA). Capryol 90® was obtained from Gattefosse 
(Lyon, France). De-ionized water was used in this study. 
 
 
5.2.2. Construction of pseudo-ternary phase diagrams 
 
 Pseudo-ternary phase diagrams were constructed to evaluate the miscibility of the 
basic components in the system at 25 oC. A series of different ratios (Km) of surfactant 
(Span 20) to cosurfactant (ethanol) were prepared at 4:1, 1:1, 1:4, and 1:9, and then 
followed by the addition of oil (Capryol 90®) at different weight ratios of oil to mixture 
of surfactant and cosurfactant of 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8 and 1:9 
respectively. Water was titrated drop by drop to the three-component mixture (under 
constant magnetic stirring) until a transition point where transformation from transparent 
(optical monophase) to turbid (optical diphase) was reached. A boundary line connecting 
all transition points was drawn, and the monophasic area AT beneath this boundary line 
was calculated using Origin 8 software (OriginLab Corporation, Northhampton, MA), 
which is shown in Figure 5-1. AT was used to evaluate water solubilization capacity into 
the oil. The following solubilization capacities AT were calculated at different 
surfactant:cosurfactant ratio Km (Km:4:1, AT:16.6, Km:1:1, AT:28.5, Km:1:4, AT:35.7, 
Km:1:9, AT:37.4). The pseudo-ternary phase diagram at a constant surfactant/cosurfactant 
ratio Km of 1:1 was chosen for further development because there is sufficient area in 
pseudo-ternay phase diagram which could form micromeulsion at this ratio while 
cosurfactant (ethanol) was kept relatively low in the formulation. A dilution line (L20) 
was plotted linking 100% water to a mixture of oil and S/COS of 20% and 80% in  
Figure 5-2.  
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Figure 5-1. Pseudo-ternary phase diagrams of mixtures composed of oil (Capryol 
90®), water, surfactant (Span 20), and cosurfactant (ethanol) at various S/COS 
ratios (Km). 
 
Shaded area represents the domain where the mixture system is monophasic. 
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Figure 5-2. Formulation selection from pseudo-ternary phase. 
 
L20 is a dilution line which connects all formulations with a fixed ratio (20/80) of oil to 
S/COS. Below the purple boundary line, the mixture exists as one phase, which is 
represented by 1φ. Otherwise, the mixture is of multiple phases, which is represented by 
M φ. 
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 Data points on this line have a constant ratio of oil to S/COS of 1:4.123,124 The 
intersection between the dilution and the boundary lines was recognized as the 
formulation with maximum water solubilization capacity. Five selected formulations 
(Table 5-1) with different water contents from L20 were further tested. Blank 
formulations were first prepared by manually mixing Span 20, ethanol, Capryol 90®, and 
water. Then formulations were incorporated with potassium iodide (KI) at a constant 
concentration of 50 mg/mL by vortex mixing. 
 
 
5.2.3. Droplet size measurements 
 
 The mean droplet size of selected formulations was determined by dynamic light 
scattering using Zetasizer Nano ZS (Malvern Instruments Inc, Westborough, MA, USA). 
Light was scattered at a fixed angle of 90°. Refractive index and viscosity values were 
inputted into the program to determine the mean droplet size accurately. All 
measurements were obtained at 25 oC. Triplicate measurements were taken. 
 
 
5.2.4. pH measurements 
 
 The pH values of selected formulations were acquired using Orion 520A pH 
meter (Thermo Fisher Scientific Inc, Pittsburgh, PA, USA). The pH probe was inserted 
into 20 mL of liquids and values were recorded when the reading stabilized. All 
measurements were done in triplicate. 
 
 
5.2.5. Viscosity measurements 
 
 The kinematic viscosities of the selected formulations were determined using 
Cannon-Fenske routine viscometer (Cannon Instrument Company, State College, PA, 
USA) at ambient temperature. Kinematic viscosity was obtained by multiplying efflux 
time of sample flowing through the capillary tube of the viscometer by the viscometer 
constant. Thereafter, the dynamic viscosity was determined by multiplying the value of 
kinematic viscosity by the sample density. All measurements were performed in triplicate. 
 
 
5.2.6. Conductivity measurements 
 
 Conductivity measurements were performed using conductivity meter FE30/FG3 
(Mettler-Toledo Inc, Columbus, OH, USA) at 25 °C. Conductivity diagram was obtained 
through drop by drop water titration to the mixture of oil and surfactant/cosurfactant 
(S/COS) at a constant ratio of 1:4 in a beaker. The conductivity sensor was soaked in the 
liquid and the reading was recorded when the signal indicating the endpoint was achieved. 
The conductivity of the five selected formulations after the incorporation of KI was 
carried out using the same methodology. All measurements were carried out in triplicate. 
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Table 5-1. Formulation composition, pH and Z-average diameter at 25 °C. 
 
Formulation Water/Span20/Ethanol/ 
Capryol 90® 
Composition (w/w %) 
KI  pH Z-average 
Diameter (nm) 
A 5/38/38/19 None 5.20±0.01 Size under detection 
limit 
B 10/36/36/18 None 5.13±0.01 1.48±0.03 
C 15/34/34/17 None 5.00±0.01 2.48±0.39 
D 20/32/32/16 None 4.94±0.01 4.36±0.04 
E 23/30.8/30.8/15.4 None 4.82±0.01 5.57±0.33 
F 5/38/38/19 0.05 g/mL 5.68±0.00 Size under detection 
limit 
G 10/36/36/18 0.05 g/mL 5.60±0.01 1.07±0.06 
H 15/34/34/17 0.05 g/mL 5.40±0.01 2.19±0.15 
I 20/32/32/16 0.05 g/mL 5.38±0.01 2.88±0.21 
J 23/30.8/30.8/15.4 0.05 g/mL 5.32±0.01 4.51±0.15 
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5.2.7. In vitro permeation studies 
 
5.2.7.1. Skin preparation 
 
 Human skin samples (chest and abdominal regions) were purchased from 
National Disease Research Interchange (NDRI, Philadelphia, PA, USA). Subcutaneous 
fatty tissues were removed from skin using a lancet after soaking the skin in a 60 °C 
water bath for 1 minute.125 Thereafter, skin samples were washed with di-ionized water. 
Prior to the actual permeation study, the fat free skin was stored refrigerated at 4 °C. 
 
5.2.7.2. In vitro diffusion experiments 
 
 To investigate KI formulation diffusion through the skin, Franz cells (PermeGear 
Inc, Hellertown, PA, USA) were utilized. The receptor volume of each cell was 5 mL and 
the diffusion area was 0.64 cm2. Prior to mounting the skin samples, each receptor was 
filled with 5 mL di-ionized water. Successively the skin samples were clamped in 
between the receptor (down) and donor (up) holding the stratum corneum side up. Prior 
to the experiment, the jacketed receptor was kept for 1 hour at 37 oC using a water bath 
with magnetic stirring. Afterwards, 1 mL of each selected formulation with 50 mg/mL KI 
was loaded to the donor compartment and each donor cell was sealed with Parafilm® to 
avoid the evaporation of formulation components. A KI solution (1 mL of 50 mg/mL 
solution) was used as the control. Then, 250 µL of the aqueous liquid were withdrawn 
from the sampling port of receptor and diluted with di-ionized water to 5 mL at different 
time points (0 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h). Simultaneously, equal volume of di-
ionized water was replaced into the liquid. The diluted samples were filtered through  
0.45 µm Millex® filter (Millipore, Billerica, MA, USA) and analyzed using Orion iodide 
selective electrode (Thermo Fisher Scientific Inc, Pittsburgh, PA, USA). Three replicates 
were carried out for each selected formulation. 
 
 The concentration of iodide in the receptor at every time point was calculated 
after incorporating the dilution factor. Then the cumulative amount of KI permeated 
across the skin per unit area (mg/cm2) was obtained by using the following Equation 5-1. 
 
Qn=
Cn ×V0+∑ Ci ×Vin−1i=1S     (Eq. 5-1) 
 
Where Cn  is the undiluted sample concentration (liquid concentration in the receptor) at 
nth sampling time point, Ci is undiluted sample concentration (liquid concentration in the 
receptor) at ith sampling time point, V0 is the receptor volume (5 mL), Vi  is the sampling 
volume (250 µL), and S is diffusion area (0.64 cm2). All Qnvalues at each time point 
were plotted as a function of time. The steady state flux (Jss , mg/cm2 per hour) was 
calculated for every formulation. Jss is the slope of linear portion of cumulative iodide 
amounts. 
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5.2.8. Accelerated microstructure stability testing 
 
5.2.8.1. Centrifugation 
 
 Selected formulations (2 mL) with and without KI were centrifuged at 13,000 rpm 
(13,793 g) for 30 minutes using Eppendorf 5415C centrifuge. 
 
5.2.8.2. Thermal stability 
 
 Selected formulations (20 mL) were stored in sealed vials at a 40 oC stability 
chamber for 4 weeks. Three replicates were carried out for each formulation. 
 
5.2.8.3. Chemical stability 
 
 Potassium iodide-starch test paper was utilized to test the existence of iodine. 
Four standard iodine solutions (2.5E-2 mg/mL, 2.5E-1 mg/mL, 5E-1 mg/mL, 1 mg/mL) 
were prepared by dissolving iodine in ethanol/water (50/50 w/w) solution. These 
standards were utilized as indicators for any presence of iodine in microemulsion 
formulations. Formulation J (23% water microemulsion with 50mg/mL KI) was selected 
to observe the presence of iodine as a function of time (0 week, 2 weeks, and 4 weeks) at 
ambient temperature. The test paper was dipped into the selected microemulsion for 30 
seconds, followed by washing with a small volume of water to provide the aqueous 
environment for the triiodide starch reaction. 
 
 
5.3. Results 
 
 
5.3.1. Construction of pseudo-ternary phase diagrams 
 
 Non-ionic surfactants are utilized in topical formulations because they are less 
irritating to skin and have less- tendency to cause allergic reactions.22 Moreover, it has 
been reported that non-ionic surfactants with poly-ethoxylated groups and/or residues 
may contain peroxides which accelerate the oxidation of iodide to iodine.126,127,128 For 
this reason, Span 20 (HLB 8.6) was selected as the surfactant since it contains no 
ethoxylated groups. In addition, Span 20 acts as a penetration enhancer which fluidizes 
the intercellular lipid bilayer.129 However, the emulsification capacity of Span 20 is 
limited since it has a relatively small polar group and a short nonpolar carbon chain. In 
order to obtain a stable microemulsion system at relatively high water content, ethanol 
was selected as a cosurfactant. Ethanol has been widely applied as a penetration 
enhancer.23 Capryol 90® (HLB 6), a common penetration enhancer, was selected as the 
oil phase.130,131 The formation of microemulsion is dependent on the assumption that 
Capryol 90® interacts with the hydrophobic chain of Span 20 in the presence of ethanol 
to lower the oil water interface. Pseudo-ternary phase diagrams were constructed to 
evaluate the miscibility of the microemulsion components.132 Mixtures of Capryol 90®, 
Span 20, ethanol and water with various Km (Span 20/ethanol, w/w) ratios are depicted in  
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Figure 5-1. AT represents the monophasic area (solubilization capacity) and it tends to 
increase as the amount of span to ethanol increases in the formulations (Km: 4:1,  
AT: 13.1; Km: 1:1, AT: 23.8; Km: 1:4, AT: 30.4; Km: 1:9, AT: 32.0). 
 
 
5.3.2. Droplet size and pH measurements 
 
 Dynamic light scattering technique measures droplet size through direct 
measurement of the droplet diffusion coefficient in a dispersed medium undergoing 
Brownian motion then the droplet size is obtained from the Stokes-Einstein equation. In 
the selected formulations, surfactant, cosurfactant, and oil form the external phase, while 
water (aqueous core) is the internal phase. The existing boundaries between oil and 
aqueous core are composed of the polar parts of Span 20, the water and ethanol. The 
results for droplet size are depicted in Table 5-1. Mean droplet size was not measurable 
for formulation containing 5% water by dynamic light scattering. These formulations 
may resemble cosolvent systems. It is possible that when water content in the system is 
low, water molecules can stay separate without the forming an aqueous droplets. As the 
water content increases to 10%, the average droplet size becomes more than 1 nm. It was 
observed that as water content further increased, droplet size of microemulsion increased 
also. 
 
 Surprisingly, the addition of KI to microemulsions shrinks water droplets. This is 
due to the salting-in effect which occurs between inorganic anionic ions such as iodide 
ions and water molecules. Thus, anionic ion makes water less polar and makes the 
organic components dissolve more readily into internal aqueous clusters.133 A schematic 
demonstration of microemulsion with and without KI is shown in Figure 5-3.  
 
It is known that iodide, a member of Hofmeister ion series, tends to increase the 
solubility of nonpolar components in aqueous solvent by decreasing the surface tension 
between water and organic molecules.134 Thus, the polar region (water content in the core) 
diminishes and the existing boundary between polar and non-polar molecules shrinks 
consequently, which causes the droplet size to decrease. 
 
 The pH values of all selected formulations were physiologically acceptable for 
topical uses. It was observed that the pH decreased from 5.20 to 4.82 when the amount of 
water increased from 5% to 23% (Table 5-1). However, after the incorporation of KI, pH 
values increased slightly from 5.68 to 5.32 (5% to 23% water content), as shown in  
Table 5-1. 
 
 
5.3.3. Viscosity measurements 
 
 Viscosity of multi-component systems is a polynomial function which depends on 
the concentrations of water, surfactant, cosurfactant, and oil in each formulation.135 
Figure 5-4 depicts the dynamic viscosity values obtained for all tested formulations in 
the presence and absence of KI as it relates to water contents. The viscosity values for 
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Figure 5-3. A schematic demonstration for the water interface of microemulsions. 
 
(a) microstructure of microemulsion without KI; (b) microstructure of microemulsion 
with KI. The internal domain represents the water content. 
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Figure 5-4. The change of dynamic viscosity as a function of water. 
 
Water is the aqueous phase of microemulsions along the dilution line L20. 
Microemulsions without KI loading are labeled as ■; microemulsions with KI loading are 
labeled as ●. 
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formulations without KI were relatively low and ranged between 9 to 11 cPoise. It was 
observed for the aforementioned formulations, viscosity increased as the water content 
increased from 5 to 23%. The observed increase in the viscosity with the water content is 
dependent upon the increase of the dispersant phase droplet’s volume and the increase in 
the frequency of collisions between the water droplets in W/O microemulsion system.136 
 
It was noted that after the addition of KI the viscosity of the formulations  
(Figure 5-4) increased slightly (10 to 11 cPoise). The increase of viscosity is not only 
due to more densed internal aqueous phase, but also due to the increase in the formation 
of aqueous transition clusters where iodide ions cause aqueous phase to become more 
hydrophobic and free to move.137 
 
 
5.3.4. Conductivity measurements 
 
 The influence of water content on conductivities of selected formulations is 
presented in Figure 5-5. The main graph relates overall ions conductivity of water 
content from 0 to 24.5%.  
 
 In general, when water molecules are dispersed in an oil phase at a small volume 
fraction, droplets are separated from each other and exhibits minimum interactions and 
liquid conductivity is low. Further addition of water increases the total number of 
aqueous droplets which can increase the formation and deformation dynamics of the 
transient clusters (aggregation of water molecules) to increase liquid conductivity. The 
cluster formation and deformation process is described in three steps: fusion, mass 
transfer and fission.138 Transient clusters have significant influence on increasing the 
conductivity. The transient collisions of water droplets provide water channels where ions 
hop from one droplet to the other.139 Therefore, a rapid increase in conductivity up to 23% 
water content was also observed. This observation is consistent with other researchers 
who described similar conductivity behavior in W/O microemulsion systems.140 
Remarkably, the addition of KI into the selected formulations enhanced conductivities 
more than 50-fold as compared to microemulsions without KI. This observation is 
consistent with the quantitative charge fluctuation model where the aqueous channels 
created by the transient clusters contain more dissociated ions which are able to facilitate 
the overall conductivity tremendously.141 
 
 
5.3.5. In vitro microemulsion skin permeation studies 
 
 Cumulative amounts of iodide that permeated through human skin over 24 hours 
for selected formulations are depicted in Figure 5-6. Results indicated that at the end of 
24 hours all KI formulations with different water contents (5%, 10%, 15%, 20%, and 
23%) had significantly better iodide permeation through skin as compared to the control 
sample (KI solution; student paired t-test, P<0.05).  
 
 Formulation F exhibited the lowest cumulative amount of iodide that permeated 
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Figure 5-5. Conductivity of microemulsion formulations along dilution line L20 
versus water content. 
 
Microemulsions without KI loading are labeled as ■; microemulsions with KI loading are 
labeled as ●. 
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Figure 5-6. Permeation profiles of KI formulations. 
 
Symbols: (■) control (KI solution); (●) Formulation F (5% water); (×) Formulation G (10% 
water); (▼) Formulation H (15% water); (▲) Formulation I (20% water); (♦) 
Formulation J (23% water). 
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the skin at the end of 24 hours out of the five selected formulations (F to J). It permeated 
about 2 times the amount of KI as compared to the solution after 24 hours. On the other 
hand, Formulation J was the most effective formulation for iodide permeation study 
(about 2.5 times of KI solutions) after 24 hours. Statistically, iodide permeation at the end 
of 24 hour for Formulation J (23% water content) was significantly higher (student paired 
t test, P<0.05) as compared to Formulation F (5% water content), but had no significant 
difference compared to Formulation G (10% water content), H (15% water content), and 
I (20% water content) (student paired t test, P>0.05). 
 
 Values of steady-state flux and cumulative amounts of iodide that permeated are 
listed in Table 5-2. Steady-state flux values (Jss) indicates that selected formulations (F to 
J) had a significant better permeation of iodide compared to KI solution. These results 
indicate that organic components in microemulsion formulations act as penetration 
enhancers. They potentially modify the lipid structure within the stratum corneum and 
make it looser and more porous for iodide permeation. Likewise, larger amount of water 
in w/o microemulsion could influence iodide permeability to a higher extent since 
Formulation J (23% water content) had the highest flux rate 0.266±0.037 mg/cm2/h. In 
the presence of water, skin is hydrated and exists in a swollen state, thus more void 
spaces within the skin create wider diffusion channels.142 In summary, the permeation 
profile of iodide within microemulsion formulations is affected by a combination of 
factors including permeation enhancement and skin hydration. 
 
 
5.3.6. Accelerated microstructure stability testing 
 
 Centrifugational forces accelerate physical instability of microemulsions and lead 
to turbidity and phase separation.143 Brownian motion maintains droplets’ kinetic energy 
which causes irregular movements of small droplets, so it prevents droplet settling. 
Additionally low interfacial tension and droplets kinetic energy lead to inhibition of 
creaming, sedimentation, flocculation, and coalescence.144 
 
 All selected formulations (A-J) in Table 5-1 in the presence and the absence of KI 
had no phase separation and clarity change by the end of 30 minutes under high 
centrifugational forces (13,000 rpm, 13,793 g) which is a sign of the strong physical 
stability of formulations. 
 
 Thermal stability testing under 40 oC showed no turbidity by the end of three 
weeks, thus lending further support to the physical stability of the microemulsion under 
thermal stress. 
 
 Chemical stability was performed by exploring the presence of degradation 
product iodine. Iodine reacts with starch in the presence of iodide and expresses blue-
black color. So we utilized iodide-starch test paper as an indicator to detect the existence 
of iodine. A series of iodine solution standards with different concentrations (Figure 5-7) 
were prepared at 0.05% (2.5E-2 mg/mL iodine), 0.5% (2.5E-1 mg/mL iodine), 1% (5E-1 
mg/mL iodine), and 2% (1 mg/mL iodine). The rational for preparing these four iodine 
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Table 5-2. Cumulative permeated iodide (Q24) and flux at steady-state (Jss) 
(mg/cm2/h) of selected formulations. 
 
Formulation 
(0.05 g/mL KI) 
Cumulative Permeated Iodide 
(Q24) (mg/cm2) 
Flux at Steady-state 
(Jss) (mg/cm2/h) 
Solution  2.38±0.66 0.127±0.036 
F 4.31±0.34 0.228±0.014 
G 5.00±0.66 0.252±0.038 
H 5.11±0.29  0.254±0.014 
I 4.88±0.50  0.245±0.029 
J 5.35±0.53  0.266±0.037 
 
 
 
 
 
 
 
Figure 5-7.   Test papers for sample stability test. 
 
From left to right: sample at 0 week, sample at 2 weeks, sample at 4 weeks, sample with 
2.5E-5 g/mL iodine, sample with 2.5E-4 g/mL iodine, sample with 5E-4 g/mL iodine, and 
sample with 1E-3 g/mL iodine. 
  
 80 
standards was related to the assumption that if the percentages of degradation of the 
initial concentration of potassium iodide in microemulsion (50 mg/mL) were 0.05%, 
0.5%, 1% and 2% then the concentrations of iodine that should be formed will be 2.5E-2, 
2.5E-1, 5E-1 and 1 mg/mL respectively.  
 
 We observed that with increasing iodine concentration the blue-black color 
became more intense. Samples were collected over 1 month period (Figure 5-7). At the 
end of one month, the absence of blue-dark color in iodide-starch test paper indicates the 
percentage of degradation product iodine is much less than 0.5%. Thus, we report with 
confidence that KI microemulsion with 23% water is chemically stable for at least one 
month. 
 
 
5.4. Discussion 
 
 Since, the dose requirement for iodide is 150 micrograms per day, a transdermal 
delivery of microemulsion iodide is feasible. In this study, we explored a W/O 
microemulsion as a vehicle which could potentially improve the permeation of iodide ion 
through skin. In this system, Capryol 90®, Span 20, ethanol, and water were combined at 
appropriate ratios. Despite the fact that other surfactants with poly-oxyethylene groups 
have better solubilization capacity than Span 20, these types of surfactants are not 
selected since the residues of peroxide originated from poly-oxyethylene groups may lead 
to the oxidation of iodide. Thus to stabilize the microemulsion, a co-surfactant is 
necessary to further decrease the interfacial tension between the oil phase and the 
aqueous phase. We have selected ethanol as the cosurfactant for this system since it is 
relatively polar and miscible with water and considered safe at a major content of less 
than 40% w/w. The addition of potassium iodide did not show any evidence of 
microemulsion destabilization. Iodide ion disrupts water-water interactions and makes 
water more hydrophobic thus forcing water dissolve more organic components including 
ethanol, Span 20, and Capryol 90® into the aqueous phase. As a result, the internal 
droplet size of water decreases. This phenomenon was also explained by other authors 
who illustrated that iodide ions adsorb and interact to the inter-phase.133 On the other 
hand, cationic ions such as potassium have subtle effect on microemulsion system. 
 
 A perspective application for this iodide microemulsion is envisioned to be in the 
therapy for specialized patients who suffer from iodide deficiency or who suffer from 
short bowel syndrome where oral absorption is limited. Currently patients with this 
illness can only rely on parental routes since the majority of nutritional elements 
including iodide may be difficult to get absorbed by GI tract. Therefore, a satisfactory 
transdermal delivery system may provide a new advent for the therapy of this disease. 
Transdermal delivery of iodide could serve as the first front for the transdermal delivery 
of nutrients. Although microemulsion is a non-toxic and non-invasive colloidal 
formulation, there are still limitations for topical use because of the poor adherence on 
the skin. A patch system of microemulsion will provide the solution for this problem. 
Such a patch will maintain the microemulsion entrapped behind the adhesive layer and 
the membrane and will control the release of the ions. 
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5.5. Conclusion 
 
 In summary, several w/o microemulsion formulations were prepared and fully 
characterized and evaluated. The physicochemical characterizations included: pH, droplet 
size, viscosity, conductivity, and stability. These studies indicated that the selected 
formulations were stable and compatible with iodide ions. The permeation studies in 
human skin showed that microemulsion enables the iodide ions to diffuse through the 
skin. Further development of this work will be to incorporate the microemulsions into a 
patch which can be applied more conveniently in clinical treatment. 
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